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Celiac disease, originally thought to occur only rarely in childhood, is now recognized 
as a common condition that might be diagnosed at any age. Due to large screening 
programs it is now well established that between 0.5 and 2% of the general population 
in the Western Hemisphere suffers from celiac disease, making celiac disease one of 
the most common food induced diseases (1,2).  
The disorder was previously called celiac sprue, based on the similarity with tropi-
cal sprue that is characterized by diarrhea, emacination, stomatitis and malabsorbtion 
(3). It is now known that celiac disease is a genetically–predisposed disease precipitat-
ed by ingestion of gluten, the major storage proteins in wheat, and similar proteins in 
related cereals like barley, rye and triticale (hybrid between wheat and rye) (4). The 
proximal small intestine is the common localization point of celiac disease related 
lesions, but in some individuals the entire small intestine is involved. As a result, mal-
absorbtion of iron, folic acid, calcium and fat-soluble vitamins occurs, which causes 
iron and folate deficiency and reduced bone density. Diarrhea is the classical sign of 
celiac disease (5,6). It usually appears when the disease has progressed to the distal 
bowel and is accompanied by abdominal pain and discomfort. Next to diarrhea, ab-
dominal distention and failure to thrive often occur in infants and young children with 
the disease while extra-intestinal manifestations as short stature, neurological symp-
toms or anemia are also encountered. Less common complications include constipa-
tion, weight loss, dermatitis herpetiformis, hypoproteinemia and elevated liver en-
zyme levels. 
For a positive diagnosis of celiac disease a histological examination of a small 
bowel biopsy and a clinical improvement upon the introduction of a gluten-free diet is 
required. Typically, the examination of the small intestinal biopsy reveals villous atro-
phy, crypt hyperplasia and intraepithelial lymphocyte infiltration. Disease severity is 
related to the extent of intestinal damage and scored conform the Marsh classification 
(7). In the past, a second biopsy would be taken after a period of gluten-free diet, 
when the small intestinal mucosa is expected to a have a normal histology and a third 
one after a gluten challenge to demonstrate that this led to deterioration. In practice 
the second and third biopsies are not always taken as the characteristic morphological 
changes in combination with the disappearance of symptoms following a gluten-free 
diet is considered sufficient proof for a positive diagnostic. Moreover, less invasive 
diagnostic methods have become available that may lead to a further reduction in the 
taking of biopsies. These serological assays measure the presence and titer of IgA anti-
bodies specific for gliadin, deamidated gliadin, endomysium and tissue transglutami-
nase (8,9). Several studies have been performed to test the sensitivity and specificity 
of these tests. While the assays measuring gliadin specific antibodies are no longer 
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considered sensitive or specific enough to be useful in the diagnosis of celiac disease, 
the assays measuring antibodies against deamidated gliadin, endomysium and anti-
tissue transglutaminase (tTg) are considered highly sensitive and specific and therefore 
widely used in the diagnosis (10,11).  
Next to patients with “classical” celiac disease, many patients have “silent” celiac 
disease. Such patients have no or only mild symptoms and truly asymptomatic individ-
uals are usually identified only after screening of high-risk groups. At the other end of 
the spectrum are patients with refractory celiac disease (RCD) (12). In such patients 
intestinal inflammation persists despite a gluten-free diet, see below.  
Thus, there is a large spectrum of symptoms and complications that can manifest, 
but it is largely unknown why this can differ so much between patients. 
The disappearance of symptoms upon the introduction of a gluten-free diet is ex-
pected. Recurrent or new symptoms should raise questions. The patients may inten-
tionally or non-intentionally ingest gluten which can be solved by closely monitoring 
their diet. Alternatively, and more seriously, a complication has developed like intesti-
nal adenocarcinoma or RCD.  Two types of RCD can be distinguished: RCD type I, with a 
normal intraepithealial lymphocyte population, and RCD type II, characterized by an 
aberrant intraepithelial lymphocyte population. RCD type II can culminate in the de-
velopment of enteropathy associated T cell lymphoma (EATL), a potentially fatal com-
plication. Treatment of RCD involves nutritional support together with a strict gluten-
free diet. The use of corticosteroids can induce clinical improvement. Treatment of 
EATL includes chemotherapy, surgical removal and stem-cell transplantation but this is 
often insufficient.  
In general, patients with celiac disease have an overall higher risk of cancers com-
pared to the general population. Next to EATL, reported cancers include T-cell and B-
cell non Hodgkin’s lymphomas, oropharyngeal and esophageal adenocarcinoma and 
cancers of the small and large intestine, hepatobiliary system and pancreas (13,14).  
Celiac disease patients also have an increased risk to develop autoimmune diseases, 
partly due to the influence of the disease predisposing HLA-molecules (see below) and 
partly due to other immune related genetic variants that influence the risk of disease 
development.   
 
 
Celiac disease: immunological aspects 
Almost without exception celiac disease develops only in genetically predisposed indi-
viduals: over 98% of the patients express either HLA-DQ2 or HLA-DQ8. The expression 
of these molecules is thus required but not sufficient for disease development as the 
majority of HLA-DQ2 and HLA-DQ8 individuals will never develop celiac disease. In 
addition to HLA-DQ, several other non-HLA genes have been identified that influence 
the likelihood of disease development but their influence is much smaller as that of 
HLA-DQ and the molecular basis for the association remains largely elusive (15-17). 
In contrast, the association of the disease with HLA-DQ became clear after the ob-
servation that gluten-specific, HLA-DQ-restricted T cell clones could be isolated from 
biopsies of celiac disease patients while such cells were not found in healthy controls 
(18). Further research revealed that these T cells respond to gluten peptides formed as 
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wheat), as most storage proteins in oat are globulins. Second, avenins contain less 
proline, the amino acid that contributes especially to the resistance of gluten to degra-
dation in the gastrointestinal tract and that is crucial for the specific modification by 
the enzyme tTG that is linked to gluten toxicity. As a result a lower amount of stimula-
tory peptides are released after oat digestion.   
There are other alternative cereals that are safe for consumption by celiac disease 
patients, all distantly related to wheat (Figure 2). Originally form Ethiopia, Teff is used 
to make a flat bread named injera. Extensive research on a selection of Teff varieties 
demonstrated that Teff protein extracts are not recognized by gluten specific T cells 
and antibodies (31). Furthermore, Teff is consumed by a large number of Dutch celiac 
disease patients without causing any symptoms (32). In addition, it is well established 
that rice and maize are safe cereals that can be introduced in the gluten-free diet add-
ing nutritional value. Moreover, sorghum and millet, more common in Africa, and Job’s 
tears, cultivated in East Asia, are also considered safe for celiac patients. As all these 
cereals are distantly related to wheat, their prolamin proteins are unlike those of 
wheat, barley and rye, hence they lack immune stimulatory sequences and are safe for 
consumption by celiac disease patients.   
Thus, the knowledge about gluten structure and phylogenetic origin helps us to 
understand why some cereals are toxic and others not, laying a sound basis for im-
provements in the gluten-free diet.  
 
 
Detection of gluten 
The only acceptable treatment for celiac disease is a gluten-free diet, but accidental 
gluten ingestion often happens. Contamination of non-toxic cereals with wheat, barley 
or rye due to co-culture or during transport, storage and/or industrial processing and 
the use of gluten as a hidden ingredient to improve the properties of different food 
products cause accidental ingestion. It is well established that commercially available 
oats is almost invariably contaminated with other cereals, excluding the use of such 
oats in a gluten-free diet (33,34).   
Exposure of patients to gluten prevents healing of gut mucosa, reactivation of 
specific T cells and reappearance of symptoms. Although not every patient is equally 
sensitive to gluten exposure, it was reported that exposure to 1 mg of gluten prevent-
ed mucosal recovery (35). Therefore, to safeguard patients from gluten exposure, 
sensitive methods for gluten detection are required and have been developed.  
Three techniques have been explored. Monoclonal antibodies raised specifically 
against gluten are most commonly used. These antibodies detect either known toxic 
gluten sequences (36-38) or highly repetitive sequences like QQPFP from gluten (39). 
Some of these antibodies have been incorporated in ELISA-immunoassays that can be 
used for detection of gluten contamination in food (40-43).   
An alternative approach is the use of Real Time PCR-techniques (34,44) using 
primes encoding repetitive sequences from gliadin.  
The third possibility is the use of mass spectrometry techniques (45). The proce-
dure is based on the determination of characteristic gliadin mass spectra and can be 
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applied for screening of both processed and unprocessed gluten containing food sam-
ples. 
In general, natural gluten-free foods should not contain over 20 ppm of gluten 
while foods rendered gluten-free should not contain over 100 ppm in order to be suit-
able for use in a gluten-free diet. Consumption by celiac disease patients of products 




The current treatment for celiac disease is strict adherence to a life-long gluten-free 
diet. The wide-spread use of gluten and gluten-derived starch in the food industry 
makes the gluten-free diet challenging. It is not surprising that a considerable propor-
tion of patients, especially adolescents, are interested in alternative treatments that 
would allow gluten consumption.   
One approach would be blocking the binding site in HLA-DQ2 and HLA-DQ8 to 
prevent the presentation of disease-inducing gluten peptides to the disease associated 
gluten specific T cells. Several groups have now designed peptide based compound 
that exhibit high affinity for the HLA-DQ2 binding site (20, 21, 22). It remains to be 
established if such compounds are indeed capable of inhibiting gluten specific T cell 
responses. 
Alternatively, compounds that would block tissue transglutaminase could be used 
to treat patients as tissue transglutaminase plays a central role in the formation of 
many gluten epitopes through deamidation (46). Thus, although T cells have been 
described that recognize non-deamidated gluten epitopes, blocking of tissue transglu-
taminase would prevent a substantial part of the gluten specific T cell response. Such 
blockers, however, are expected to exhibit side effects, like impaired wound healing, 
limiting the applicability of this approach.    
The perhaps most promising approach is the use of exogenous enzymes to im-
prove gluten degradation in the gastrointestinal tract. It has been proposed that oral 
administration of a prolyl endoprotease might counteract the damaging effects of 
moderate amounts of gluten.  Prolyl endoproteases can cleave the proline rich im-
munostimulatory gluten fragments, creating in this way new cutting sites for the en-
zymes residing in the gastro-intestinal tract.  Several enzymes have been proposed, 
either in single (47,48) (49-51) or in combination therapies (52,53) and their efficiency 
was proved in vitro, in vivo (rats) and in ex vivo (T cell cultures) experiments. If these 
enzymes are indeed capable of degrading gluten proteins efficiently in the gastrointes-
tinal tract remains to be determined. 
Finally, the development of grains that contain no or low toxic gluten proteins, 
the holy grain, is an attractive alternative.  Potentially, such grains can be developed by 
breeding diploid wheat varieties, incorporation of non-toxic gluten genes into harmless 
cereals such as rice, small RNA interfering technology or mutation of genes encoding 
the immunostimulatory sequences. Although such approaches are likely to prove to be 
a challenge, the existence of such a grain could form the base for a nutritionally im-
proved diet for celiac disease patients.     
 





My project has focused on the development of alternatives to the gluten-free diet. 
Two different approaches were investigated: the use of enzymatic supplementation 
and the identification and/or development of a less/non-toxic cereal.  
In chapter 2 the characterization of monoclonal antibodies raised against T cell 
stimulatory gluten peptides is described. Their reactivity against the prolamins from 
wheat, barley, rye and oats was determined and compared with that of gluten reactive 
T cells. The results demonstrate that the antibody and T cell reactivity patterns overlap 
significantly, indicating that the antibodies can be used to detect toxic sequences in 
gluten. Subsequently, these antibodies were used in the studies aimed at the devel-
opment of alternative to the gluten-free diet.  
In chapter 3 we propose a new strategy to generate non-toxic gluten. Our exper-
iments demonstrated that non-immunogenic epitope variants were present in certain 
diploid wheat varieties that differ one amino acid with the toxic variant.  Moreover, we 
found that by the introduction of this naturally occurring amino acid substitution in 
other toxic epitopes their T cell stimulatory activity was likewise eliminated. This ap-
proach can thus be used to generate gluten genes that are devoid of any T cell stimula-
tory activity and presumably safe for consumption by celiac disease patients.  
In chapter 4 we investigate the safety of oats for consumption by celiac disease 
patients. We confirmed that commercially available oats are without exception con-
taminated with other cereals. Perhaps more importantly, we demonstrate that con-
tamination-free oat varieties differ in their capacity to stimulate an avenin-sensitive 
gamma-gliadin specific T cell line derived from a patient with CD, opening the way to 
select and/or breed oats varieties that contain no harmful gluten-like proteins.  
In chapter 5 we investigate the potential of AN-PEP, a prolyl-endoprotease pro-
duced by the microorganism Aspergillus niger, to degrade gluten in an artificial gastro-
intestinal tract system. The enzyme proved very efficient in degrading all toxic epitopes 
in this system, even when a complex meal was introduced. These “in vitro” studies 
now justify a clinical trial to assess the safety and effectiveness of the enzyme for glu-
ten degradation in patients. 
In chapter 6 I discuss how the results may lead to novel treatment modalities and 
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In Celiac Disease (CD) patients peptides, derived from dietary gluten, are recognized by 
HLA-DQ2 restricted CD4
+
 T cells which results in inflammation. Such immune-stimula-
tory peptides are found in both gliadins and glutenins. Monoclonal antibodies (mAb) 
against these peptides can be used to screen food for the presence of such peptides. 
We aimed to determine specificity of five mAb raised against T cell stimulatory pep-
tides found in α- and γ-gliadins and low and high molecular weight glutenins and to 
compare it this with the specificity of patient-derived T cells. Moreover, to determine 
the suitability of these mAb for the detection of homologous proteins in barley, rye 
and oat. The reactivity of the mAb with gluten peptides, enzymatic gluten digests and 
intact gluten proteins was determined and compared with that of gluten-specific T 
cells using a combination of immunological and biochemical techniques. Furthermore, 
the reactivity of the mAb with gluten homologues in barley, rye and oat was deter-
mined. The specificity of the mAb largely overlaps with that of gluten-specific T cells. 
Moreover, the mAb detect several homologous peptides present in gluten proteins. All 
except the LMW-specific mAb also detect storage proteins present in barley and rye, 
while the γ-gliadin-specific mAb also recognises oat proteins. The mAb raised against T 
cell stimulatory peptides in gliadins and glutenins allow a comprehensive screen for 
the presence of harmful gluten and gluten-like proteins and peptides in food products. 










Celiac disease (CD) is caused by intolerance to gluten, storage proteins found in wheat. 
Typical symptoms are chronic diarrhoea or constipation, malnutrition, anaemia, fa-
tigue, growth retardation and migraine. These symptoms are the result of an inflam-
matory process that causes (sub) total villous atrophy in the small intestine which 
decreases the normal uptake of nutrients from food. With an incidence of 0.5-1.0%, CD 
is the most common immune-mediated food intolerance in the Western world.  
During digestion, the gluten proteins are enzymatically broken down in the gas-
trointestinal tract. However, because of the high proline content of the  gluten pro-
teins, the degradation is not efficient and relatively large gluten peptides persist (1,2). 
In CD patients such gluten peptides, when bound to the disease-predisposing HLA-DQ2 
or HLA-DQ8 molecules, can trigger a CD4+ T cell mediated inflammatory immune re-
sponse(3-5). The gluten-derived peptides that trigger the inflammatory CD4+ T cell 
responses originate from proline- and glutamine-rich regions of α- and γ-gliadins and 
from the low (LMW) and high molecular weight (HMW) glutenins (6-8). Next to wheat 
also other cereals like barley, rye and oat contain storage proteins, the hordeins, se-
calins and avenins respectively. These related storage proteins can also trigger the 
immune system of CD patients (9). The collection of all gluten and gluten-like proteins 
is referred to as the gluteome (10). 
A strict lifelong gluten-free diet is currently the only available treatment for CD. 
This diet is complicated by the fact that gluten is extensively used in the food industry 
and, as a result, can be found in many products that are not normally associated with 
gluten or wheat, including sauces, sweets and medication. According to the guidelines 
of the Codex Alimentarius gluten-free food should contain less than 200 ppm gluten 
when rendered gluten-free and less than 20 ppm when naturally gluten-free, as men-
tioned in the Report of the 25
th
 Session of the Codex Alimenatrius Committee on Nutri-
tion and Foods For Special Dietary Uses, Bonn 2003. Most likely the acceptable level 
for rendered gluten-free foods will be reduced in the near future as in a new draft for 
the standards by the Codex Alimentarius a maximum level of 100 ppm is recommend-
ed (//ftp.fao.org/codex/ alinorm07/al30_26e.pdf). To determine if foods intended for 
the gluten-free market meet these strict requirements sensitive assays for gluten de-
tection are required. The detection of gluten in food is complicated as gluten is a large 
family of proteins that is divided into two biochemical distinct subfamilies, the gluten-
ins and gliadins. The former can be further subdivided into the LMW- and the HWM-
glutenins while the latter can be further subdivided into α-, γ- and ω-gliadins, and each 
of these groups consists of a mixture of highly similar but distinct proteins (11). Anoth-
er factor complicating the detection of gluten is that both intact gluten proteins and 
gluten hydrolysates are used in the food industry. This means that, ideally, gluten de-
tection assays should be able to detect both intact gliadins and glutenins and frag-
ments thereof. Moreover, since the disease-related T cell stimulatory peptides of glu-
ten have been identified, it would be a major advantage if such gluten detection assays 
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would specifically detect these peptides rather than indicate a level of overall gluten 
content.   
In order to develop a robust assay that would meet these requirements we have 
developed mAbs against T cell stimulatory peptides present in α- gliadin (Glia-α9, Glia-
α20 epitopes), γ-gliadin (Glia-γ1 epitope), LMW-glutenin (Glt156) and HMW-glutenin. 
Some of these antibodies have already been used to develop highly sensitive competi-
tion assays for the detection of proteins and peptides that harbour these sequenc-
es(12-14).  
In the present study, an extensive characterization of the specificity of these mAb 
was carried out to determine their usefulness for the detection of various gluten and 
gluten-like peptides present in cereals that are implicated in CD.  
 
 
MATERIALS AND METHODS  
 
Generation of monoclonal antibodies 
For the generation of mAb Balb/c mice were immunized with synthetic peptides corre-
sponding to known T cell stimulatory epitopes that were coupled to tetanus toxoid 
(Table 1). Fusion, purification and screening of the hybridomas were performed as 
described previously (12-14). 
 
Database searches 
Searches were performed in the UniProt kB database for variants of the the Glia-α9, 
Glia-α20, Glia-γ1, LMW- and HMW-glutenin gluten epitopes using FASTA alignment as 
described (15). The following sequences were used in the searches: Glia-α9: 
QLQPFPQPQLPY/E; Glia-α20: PFRPQQPYPQPQPQ; Glia-γ1: QQSFPQQQRPFIQPSL; LMW: 
PPFSQQQQSPFS. For the variants of the HMW epitope previously described results 
were used (7). Variants of the Glia- α2, Glia-α9, Glia-α20, Glia-γ1 epitopes present in 
gluten-like proteins from barley, rye and oat were identified previously (15). 
 
Synthetic peptides 
Peptides were synthesized by standard Fmoc chemistry on a SyroII peptide synthesizer 
as described previously. The integrity of the peptides was checked by rpHPLC and mass 
spectrometry. When required, Biotin was introduced in the resin-bound peptides by a 
two hour coupling with a 6-fold equimolar preactivating mixture of biotin and ben-
zotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBop). 
 
Peptide recognition assay  
Elisa plates (Nunc Maxisorb immunoplate, Nunc, Copenhagen, Denmark) were coated 
overnight (100 µl/well) at room temperature with the various antibodies in a concen-
tration of 2-5 µg/ml in phosphate buffered saline (PBS, 154 mM NaCl, 1.4 mM 
Na2HPO4/NaH2PO4 pH 7.4). The plates were washed with PBS/0.02% (w/v) Tween-20 
and the residual binding sites on the plates were blocked by incubation for 30 minutes 
at room temperature with 150 µl/well 2% skim milk in PBS (Fluka, Zwijndrecht, The 
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Netherlands). After a washing step, the plates were incubated for 1 hour with the 
biotinylated peptides in a concentration range of 0.5-2 µg/ml in PBS/0.2% Tween-20/ 
0.2% skim milk. After this step, the plates were washed and incubated for 30 minutes 
with an excess of streptavidin-HRP (Sigma Aldrich, Zwijndrecht, The Netherlands). 
After a washing step, bound peroxidase was visualised by incubation with a solution of 
3,3’,5,5’-tetramethylbenzidine (TMB, Sigma Aldrich). The colour reaction was stopped 
by the addition of 100 µl/well 2M H2SO4. Finally, absorbance was read on a multiscan 
plate reader (Wallac, Turku, Finland). 
 
Direct binding assay 
Direct binding assays were, in general, performed like the peptide binding assay. In 
short, Elisa plates (Nunc Maxisorb immunoplate, Nunc,Copenhagen, Denmark) were 
coated overnight at room temperature with the various peptides in a concentration 
range of 10-1,25 µg/ml in PBS, 100 µl/well. The plates were washed and the residual 
binding sites were blocked. After a washing step, the plates were incubated for 1 hour 
with the various mAb at a concentration of 1,5 µg/ml in PBS/0.2% Tween-20/ 0.2% 
skim milk. After this step, the plates were washed and incubated for 30 minutes with 
an excess of rat-anti-mouse, HRP conjugated polyclonal antibodies (Sigma Aldrich). 
After a washing step, the assay was stained and absorbance was read as described 
above. 
 
Immune precipitation assay 
For immune precipitation, a pepsin/ trypsin digest of wheat flour was incubated with 
the various monoclonal antibodies covalently coupled to sepharose beads (2-3 mg/ml). 
After 120 minutes of gentle mixing at 4°C, the beads were washed sequential with 120 
mM NaCl, 20 mM Tris HCl pH 8.0; 1 M NaCl; 20mM Tris HCl pH 8.0; 20 mM Tris HCl pH 
8.0 and 10 mM Tris HCl pH 8.0. Bound peptides were eluted with 10 ml 10% (v/v) ace-
tic acid and analysed by mass spectrometry followed by database searches as de-
scribed previously (10). 
 
T cell proliferation assays 
Proliferation assays were performed in triplicate in 150 μl RPMI-1640 (Gibco) supple-
mented with 10% human serum in 96-well flat bottom plates (Falcon) using 2 x 10
4 
gluten-specific T cells stimulated with 10
5  
irradiated HLA-DQ2-matched allogenic 
PBMCs (3000 RAD) in the presence of 1 μg peptides. All the peptides were deamidated 
by tissue transglutaminase (tTg) (BioTec, GmbH) in the presence of CaCl2, overnight at 
37° C. After 48 hours at 37° C, cultures were pulsed with 0.5 μCi of 
3
H-thymidine, har-
vested 18 hours later and the 
3
H-thymidine incorporation was quantified with a liquid 
scintillation counter.  
 
Protein analysis by 1D SDS-PAGE and Western blotting  
SDS-PAGE (12.5 % acrylamide gel) was performed under standard conditions. After 
separation proteins were either stained with Imperial
TM
 Protein Stain (Pierce, Rockford 
IL, USA) or transferred to Polyvinylidene Difluoride (PVDF) membranes (Bio-Rad, Her-
 
c
stimulatory T cell epitopes from 
 
In gel digestion of proteins
The desi
motrypsin using the Proteineer DP digestion robot (Bruker, Bremen, Germany). The 
protocol supplied by the manufacturer was followed. Digested proteins were
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amino acid sequence of the T cell stimulatory epitopes coupled to tetanus toxoid. The minimal 
amino acid sequence recognized by gluten specific T cells is underlined.
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The minimal epitopes recognized by the mAb was determined in a peptide recognition assay by 
testing their reactivity against a set of overlapping peptides. The sequence recognized by the 
mAb is indicated in boxes. (A) anti-Glia-α20 mAb (B) anti-HMW- glt mAb. 
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Figure 1. Minimal epitope recognized by mAb raised against T cell stimulatory epitopes of 
gliadin and glutenin. 
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Glia-α9 and the Glia-γ1 epitopes were determined previously (13). With the use of a 
set of partially overlapping synthetic peptides the minimal amino acid sequences rec-
ognized by the mAb specific for the Glia-α20, LMW- and HMW-glutenin peptides were 
determined. Representative results are shown in Figure 1 while an overview of all 
results is given in Table 2. The results indicate that the sequence recognized by the 
mAb specific for the Glia-α9, Glia-α20 and HMW-glutenin peptides largely overlap with 
the T cell stimulatory sequences (Table 2). In contrast, the mAb specific for the Glia-γ1 
and LMW-glutenin epitopes recognize sequences that (partially) overlap with either 
the C- or N-terminus of the T cell epitopes (Table 2). 
 
 
The minimal amino acid sequence recognized by human T cells is underlined and the 




 LMW- glt=low molecular weight glutenin 
3
 HMW-glt=high molecular weight glutenin 
4
 mAb=monoclonal antibody   
 
 
As many gluten proteins share a high degree of homology, we determined next if 
the mAb reacted specifically only with the peptide used for immunization or if they 
also detected the other T cell stimulatory sequences. The results (Figure 2A, 2B, 2D, 
2E) indicate that the mAb specific for the Glia-α9, Glia-γ1, LMW- and HMW-glutenin 
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Table 2. Comparison of minimal amino acid sequences recognized by gluten specific mAb and 
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Monoclonal antibodies and gluten specific T cells recognize an overlapping 
set of natural gluten derived homologues of the T cell stimulatory epitopes 
In previous studies it was shown that human gluten-specific T cells can react to several 
homologous gluten peptides if these share a certain degree of sequence similarity (16). 
In order to compare the specificity of the human T cells with that of the gluten specific 
mAb, natural variants of the Glia-α9, Glia-α20, Glia-γ1, LMW- and HMW-glutenin 
epitopes were identified by database searches. Subsequently, the corresponding pep-
tides were synthesized and the reactivity of T cells and mAb to these peptides was 
determined.  
Eleven variants of the Glia-α9 T cell epitope (QLQPFPQPQLPYPQP, the minimal 9 amino 
acid T cell epitope is underlined) (17) were identified that contain single or multiple 
substitutions. In general, substitutions in the region flanking the minimal epitope af-
fected T cell and mAb recognition in the same way (Figure 3A). Substitutions within the 
9 amino acid core sequence at positions 3, 4 and 5 significantly reduced or even abol-
ished both T cell and mAb recognition while a substitution at position 8 affected T cell 
recognition only. This latter is due to the fact that position 8 is outside the antibody 
epitope (Table 2).  
In total four out of the twelve peptides tested were detected by both T cells and mAb, 
three were detected by T cells only, two by mAb only and the remaining three by nei-
ther (Figure 3A, B). Thus, the specificity of the T cells and the antibody partially over-
laps.  
A similar analysis was performed for the other antibodies, a graphical representation 
of the results obtained is shown in Figure 3B. Of 21 variants of the Glia-α20 T cell 
epitope, six were recognized by T cells and mAb, ten by T cells only and one by mAb 
only (Figure 3B). Also for the eight variants of the LMW-glutenin epitope and the 33 
homologues of the HMW-glutenin epitope it was observed that a subset was detected 
by both T cells and mAb (Figure 3B).  In contrast, of the six variants of the Glia-γ1 
epitope only one is recognized by the T cells while two others are recognized by mAb 
only. Thus, with the exception of the Glia-γ1 mAb, all other mAb react with multiple 
variants of the T cell epitopes. 
 
Gluten specific mAb recognize their epitopes in pepsin/ trypsin digests of 
wheat flour  
Next, we determined the reactivity of the mAb against a pepsin/trypsin digest of 
wheat flour. For this purpose the mAb were covalently coupled to sepharose beads 
and incubated with a pepsin/trypsin digest of gluten. Subsequently, unbound material 
was removed by extensive washing and the bound material eluted with acid and ana-
lyzed by mass spectrometry. This approach was successful with the Glia-α9, Glia-α20, 
LMW-glutenin and HMW-glutenin mAbs. In all cases the mass spectrometric analysis 
identified peptides that contained the minimal amino acid sequence for which these 
mAb are specific. The five most abundant peptides identified for each mAb are shown 
in Table 3. These mAb thus react with gluten peptides that are naturally formed during 
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Table 3. Protein fragments precipitated by gluten specific mAb 
Amino acid sequence of gluten peptides detected by the gluten-specific mAb in a pepsin/trypsin 
digest of gluten. The five most abundant peptides are shown. Mab epitopes are in bold, variants 
of the epitopes are in italic. 
1
 Anti-Glia-α9=anti gliadin alpha-9 antibody 
2
 Anti-HMW-Glt=anti high molecular weight glutenin antibody 
3
 Anti-LMW-Glt=anti low molecular weight glutenin antibody 
 
 
Gluten specific antibodies show the presence of T cell stimulatory epitopes in 
various gluten proteins 
To study the suitability of the mAb for the detection of gluten proteins, these were 
extracted with isopropanol/DTT from a wheat variety and separated on SDS-PAGE. 
Subsequently, the proteins were either stained directly with Coomassie blue or, after 
transfer to a membrane, by the gluten specific mAb in a Western blot analysis (Fig-
ure  4). To identify the proteins stained by the various mAb in the Western blot analy-
sis, gel slices were excised from the Coomassie blue stained gel at positions corre-
sponding to the mAb stained bands. Subsequently the proteins in these gel slices were 
isolated, digested with chymotrypsin and analyzed by mass spectrometry. All chymo-
trypsin fragments isolated from the gel slice corresponding to the proteins stained by 
the HMW-specific mAb (Figure 4, lane 2, proteins 1 and 2) were found to be derived 
from HMW-glutenin proteins. These fragments contained multiple copies of the mini-
mal amino acid sequences recognized by both the mAb and T cells specific for HMW-
glutenin (results not shown).  Similarly, both of the proteins recognized by the anti-
LMW-1 mAb (Figure 4, lane 3, proteins 3 and 4) were identified as LMW-glutenin pro-
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T cell (results not shown). The gel slices corresponding to the regions stained by the 
Glia
found to contain α/β




Thus, the mAb are useful for the detection of gluten proteins that harbour harmful 
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 Table 4. Gluten epitopes and the homologous peptide sequences found in hordein, 
































Cereal storage protein sequences were obtained by database searches using the protein family  
as keyword  (15) (Table 1). T cell stimulatory sequences are underlined. Sequences recognized  by 
mAb are shown in bold. The elongated residues are indicated in grey. 
 
  
Gliadin α2/ α9 PYLQLQPFPQPQLPYPQPQLPYPQPQ
Secalin α2             QPFPQPQQPFPQSQ
Hordein α2              QQFPQPQQPFPQQP
Gliadin α2/α9 PYLQLQPFPQPQLPYPQPQLPYPQPQ
Secalin α9        PQQPFPQPQQPFPQ
Hordein α9        PQQPFPQPQQPFRQ
Avenin α9I        QYQPYPEQQEPFVQ
Avenin α9II        QYQPYPEQQQPFVQ
Gliadin α20 PQPFRPQQPYPQQP
Hordein α20 QQPFPPQQPFPQQP










Reactivity of the mAb against gluten and gluten
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To demonstrate that the mAb were capable of detecting hordeins, secalins and aven-
ins, protein extracts of five cereals (wheat, barley, oat, rye and triticale) were prepared 
and separated by SDS-PAGE. Subsequently, the proteins were stained with the mAb in 
a Western blot analysis (Figure 6, Table 5). A commercial gluten preparation was used 
as a positive control. As expected the staining pattern of the gluten preparation and 
the wheat protein extract were very similar. In contrast, distinct staining patterns were 
observed for oat, rye and barley, while the staining pattern of triticale, a hybrid con-
taining both the wheat and the rye genome, closely matches the sum of the staining 
patterns of wheat and rye. The results (Figure 6, Table 5) indicate that the Glia-α9 mAb 
reacts with all cereals except oat. The HMW mAb only reacts with wheat and rye and 
the LMW mAb only with wheat. The reactivity of the HMW mAb with rye is presumably 
based on the presence of proteins in rye that have a high degree of homology with 
both the x- and y-type of HMW-glutenins of wheat (18).  The staining patterns ob-
tained with the Glia-α20 and Glia-γ1 mAb are more complex, the latter having a high 
affinity for the oat proteins.  
The results also indicate that the mAb-staining patterns obtained are distinct for 
each cereal. This may be useful for the identification of the type of (contaminating) 
cereals present in (gluten-free) food products. 
 
Gluten specific antibodies do not react with milk proteins 
As the gluten specific antibodies are used in assays where milk is employed as a block-
ing agent we tested if the antibodies cross-react with proteins in milk as an additional 
control for the assay. For this, a Western blot analysis was performed. Milk was diluted 
in water and the proteins precipitated with acetone. Subsequently the proteins were 
separated on SDS-PAGE, transferred to blots and stained with the antibodies against 
Glia-α9, Glia-α20, Glia-γ1, LMW- and HMW-glutenin gluten epitopes.  None of the 
antibodies reacted with proteins in milk while gluten proteins were clearly detected 
(Figure 7). 
 
Comparison of Ridascreen® Gliadin kit and the Home made Elisa for the  
Glia-α9 epitope. 
A commercial test kit is now available based on the R5 monoclonal antibody specific 
for the sequence QQPFP. As this sequence partially overlaps with that recognized by 
the mAb specific for the alpha-9 T cell epitope (QPFPQPQ) we have compared the 
reactivity of the alpha-9 specific mAb with that of the R5 antibody. For this purpose we 
tested a number of samples with both our mAb against the alpha-9 peptide and with 
the commercially available R5 based test kit (Table 6). Gluten-free samples tested were 
negative in both assays (not shown). Gluten containing samples could easily be detect-
ed by both assays although the actual values obtained varied. In general the values 
obtained with the competition assay were higher as those obtained with the R5. This 
may be due to the standards used in the two assays, a complex gliadin preparation in 
the case of the R5 based assay versus synthetic peptides for the competition assay. An 
in depth comparison of these two assays is planned. 
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Table 6. Comparison of Ridascreen® Gliadin kit and the Glia-α9 specific assay. 




 specific assay [ppm] 
toast “LePoole” 1.52 8.08 
butter biscuits “LePoole” 20.67 27.19 
cake bakery “De Wijn” 3.15 18.66 
flour “LePoole Twelloo’s” quinoa 2.81 11.23 
couscous “Nestle” >> 349.9 
Gluten containing samples were tested with both the Ridascreen® gliadin, based on the R5 anti-
body, and the assay specific for the Glia-α9 epitope developed in our laboratory. 
1







It is well established that celiac disease is caused by intolerance to gluten. With few 
exceptions celiac disease only develops in individuals that are either HLA-DQ2 or HLA-
DQ8 positive. The extraordinary strong association between these HLA-DQ molecules 
and the development of celiac disease points to a crucial role for these HLA-DQ mole-
cules in disease development. Recent work has revealed the basis for this association: 
HLA-DQ2 and HLA-DQ8 can bind gluten-derived peptides and present these to inflam-
matory T cells that are present in the small intestine of celiac disease patients, leading 
to disease (19-21) Consequently, the gluten-derived peptides that can bind to HLA-
DQ2 or HLA-DQ8 and stimulate T cells are the true culprits and should not be present 
in food intended for consumption by celiac disease patients.  
Importantly, such T cell stimulatory gluten peptides have now been identified in 
α- and γ-gliadin and LMW- and HMW-glutenin. Both gliadins and glutenins are multi-
protein families with a high degree of sequence homology between different mem-
bers. Therefore, variants of the identified T cell stimulatory peptides are known that 
can also elicit T cell responses (7). Moreover, peptides with similar T cell stimulatory 
properties have been identified in barley, rye and oat as well (15). In order to guaran-
tee the safety of food products intended for the gluten-free market it would therefore 
be highly desirable to use tools that detect as many of the potentially harmful gluten 
and gluten-like fragments as possible. 
With this in mind, mAbs were raised against non-deamidated forms of known T 
cell stimulatory peptides present in gluten. This will allow detection of native gluten 
peptides that upon deamidation by tissue transglutaminase in the small intestine can 
trigger an immune response. We aimed at detecting both the alpha- and gamma-
gliadins and HMW and LMW glutenins. With these antibodies we can thus monitor the 
presence of 4 different classes of gluten proteins which is a large improvement com-
pared to the existing assays based on the R5 mAb that only recognizes gliadin proteins. 
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In this paper we provide a detailed analysis of the reactivity of these antibodies 
against gluten proteins, gluten peptides, and gluten-like proteins present in barley, rye 
and oat. The minimal amino acid sequences detected by these mAb were determined 
and found to partly overlap with that of T cell stimulatory gluten sequences. Moreover, 
as gluten-specific T cells do (13), the mAb were found to react not only with the pep-
tide against which they were raised but also with homologous gluten proteins and 
peptides present in wheat, barley, rye and oat. In addition the proteins recognised by 
the mAb did contain epitopes involved in CD. By Western blot analysis these antibod-
ies were found to give characteristic staining patterns depending of the cereal being 
analyzed, a property that may be useful for the identification of the type of cereal 
present in and/or contaminating particular food products.  
Next to its reactivity with gluten and gluten-like proteins and peptides, the mAb 
against the Glia-γ1 epitope also reacted strongly with oat, a finding that may be ex-
plained by the homology between the N-terminal sequence of the Glia-γ1 T cell 
epitope: QQRPFI and an amino acid sequence that is frequently present in the α- and 
γ-avenins: QQQPFV. Similarly, oat protein can be recognized by Glia-γ1 specific T cells 
(13), although it should be indicated that the specificity of the mAb and T cells overlap 
only minimally (Table 2). 
In separate studies it was tested if the antibodies react with proteins from teff, 
rice and maize, cereals that are non-toxic for celiac disease patients. In all instances we 
observed reactivity with wheat, rye and/or barley only (22). 
The Codex Alimentarius defines gluten-free foods as those whose gluten contents 
is below 200 ppm for wheat starch containing food products and below 20 ppm for 
naturally gluten-free food products. In a new draft for the standards used for gluten-
free food products the level of 100 ppm for food rendered gluten-free is recommend-
ed (//ftp.fao.org/codex/alinorm07/al30_26e.pdf). The best known commercially avail-
able assays for the detection of gluten are sandwich ELISA’s based on the R5 antibody, 
which is specific for a common sequence present in α-, -β, and -γ gliadins (23), and on 
an antibody directed against a sequence in ω-gliadin (24).  However, as these sequenc-
es do not match T cell stimulatory gluten peptides these assays do not measure the 
presence of harmful fragments for CD patients. Moreover, these assays fail to detect 
the HMW- and LMW-glutenins while there is mounting evidence that these proteins 
are harmful for CD patients as well (7;8;17;25). With the availability of antibodies spe-
cific for α- and γ- gliadins as well as LMW- and HMW-glutenins, assays can now be 
developed that overcome these problems. Moreover, as these antibodies do not only 
react with gluten proteins but with peptides as well, they are suitable for use in com-
petition assays in which not only intact gluten proteins can be measured but also glu-
ten peptides of sizes recognised by T cells. This is of particular interest as gluten hy-
drolysates are often used in the food industry and these cannot be measured in sand-
wich ELISA’s.  
In conclusion, the antibodies described in this study allow a comprehensive 
screen for the presence of harmful gluten and gluten-like peptides and proteins in 
foods intended for consumption by CD patients with a level of detail that is as yet un-
precedented. This will likely contribute to food safety and thereby the quality of life of 
CD patients. 
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Celiac disease is caused by an uncontrolled immune response to gluten, a heterogene-
ous mixture of wheat storage proteins, including the α-gliadins. It has been shown that 
α-gliadins harbor several major epitopes involved in the disease pathogenesis. A major 
step towards elimination of gluten toxicity for celiac disease patients would thus be 
the elimination of such epitopes from α-gliadins. We have analyzed over 3000 ex-
pressed α-gliadin sequences from 11 bread wheat cultivars to determine whether they 
encode for peptides potentially involved in celiac disease. All identified epitope vari-
ants were synthesized as peptides and tested for binding to the disease-associated 
HLA-DQ2 and HLA-DQ8 molecules and for recognition by patient-derived α-gliadin 
specific T cell clones. Several specific naturally occurring amino acid substitutions were 
identified for each of the α-gliadin derived peptides involved in celiac disease that 
eliminate the antigenic properties of the epitope variants. Finally, we provide proof of 
principle at the peptide level that through the systematic introduction of such natural-
ly occurring variations α-gliadins genes can be generated that no longer encode anti-
genic peptides. This forms a crucial step in the development of strategies to modify 
gluten genes in wheat so that it becomes safe for celiac disease patients. It also pro-
vides the information to design and introduce safe gluten genes in other cereals, which 









Celiac Disease (CD) is an intestinal T cell-mediated disease caused by the gluten frac-
tion of wheat or the homologous proteins from barley or rye. CD has prevalence be-
tween 0.5 and 2% in human populations [1] and is characterized by a chronic intestinal 
inflammation upon ingestion of gluten proteins. Recently, the molecular aspects have 
been comprehensively addressed in several review papers [2-5]. In short, in CD pa-
tients CD4+ T cells are present in the lamina propria that secrete interferon-gamma 
upon recognition of gluten-derived peptides bound to HLA-DQ2 or HLA-DQ8 molecules 
present on antigen presenting cells. Strikingly, most of the gluten peptides implicated 
in CD require modification by the enzyme tissue transglutaminase before they can bind 
to the disease-predisposing HLA-DQ molecules and trigger T cell responses [2-5]. In 
addition to the adaptive CD4+ T cell response to gluten, CD is characterized by the 
upregulation of IL-15, an intraepithelial T cell infiltrate expressing the NKG2D receptor, 
and the overexpression of a ligand for NKG2D (MICA) [6, 7].  
Many gluten peptides with T cell stimulatory properties have now been identified. 
Such peptides have been found in wheat α-, γ-, and ω-gliadins as well as in low mo-
lecular weight (LMW) and high molecular weight (HMW) glutenins [8-14]. Several stud-
ies have demonstrated that peptides derived from α-gliadins induce strong T cell re-
sponses in the large majority of patients, while responses to the other peptides are 
less frequently found [8-10, 13]. An α-gliadin derived 33-mer peptide (amino acid se-
quence LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF) was identified that encodes six 
partially overlapping T cell epitopes and has very potent T cell stimulatory properties 
[13]. It harbours the p56-75 peptide (LQLQPFPQPQLPYPQPQLPY) that has been identi-
fied as the dominant gluten epitope [9, 10]. Furthermore, α-gliadins are the only glu-
ten molecules that harbor the p31-43/49 peptide that has been implicated in the in-
nate immune response induced by gluten [7].  
The α-gliadins are a gene family encoded by the Gli-2 loci, Gli-A2, Gli-B2 and Gli-
D2, located on the short arm of three homoeologous chromosomes (6AS, 6BS and 6DS) 
of hexaploid bread wheat (Triticum aestivum L.). These loci may contain from 25-35 to 
even 150 α-gliadin genes per haploid genome [15-17], although most of these (72-
95%) are presumably pseudogenes [16,17]. Sequencing of genomic α-gliadin clones 
from hexaploid bread wheat enabled to differentiate the sequences according to their 
loci Gli-A2, Gli-B2 and Gli-D2 based on genome-specific SNPs [16,17]. Relevant for CD, 
the occurrence and frequency of the HLA-DQ2 epitopes DQ2-Glia-α1, DQ2-Glia-α2 and 
DQ2-Glia-α3 (previously designated Glia-α20, ref. 12] and the HLA-DQ8 T-cell epitope 
DQ8-Glia-α1 also differs between the loci [17]. This was corroborated by the observa-
tion that T cell clones specific for the DQ2-Glia-α2 epitope did not recognise gluten 
derived from diploid species carrying the S-genome, ancestrally related to the B ge-
nome of bread wheat, while gluten derived from diploid A- and D-genome species was 
recognized [18]. Variation in T cell stimulatory capacity of cereal-derived gluten was 
observed with other T cell clones as well [19-21]. Indeed, differences have been ob-
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served in the T cell stimulatory capacity of pasta and bread wheat varieties [22,23], but 
none were safe for CD patients. 
Given the overall importance of the α-gliadins in CD we set out to determine the 
naturally existing sequence variation in CD epitopes as deduced from α-gliadin tran-
scripts from developing wheat grains. The immunogenic potential of these epitope 
variants was subsequently tested in T-cell proliferation assays. This produced insight in 
which key amino acid changes are sufficient to abolish T-cell recognition. Finally, we 
verified that the observed differences in antigenicity of α-gliadin peptides derived from 
diploid species corresponded to differences in the antigenicity of the gluten from these 
species, ancestrally related to bread wheat. Altogether the results offer a molecular 
basis for differential CD toxicity of the wheat genomes. Based upon these results we 
present a rational strategy to develop genes that encode α-gliadins that are safe for 





Genetic variation in α-gliadin (Gli-2) transcripts 
In total 3022 expressed α-gliadin sequences (expressed sequence tags and mRNA se-
quences from NCBI and Unigene) originating from 11 different T. aestivum L. varieties 
were analyzed. These α-gliadin transcripts were grouped into 55 contigs with at least 
90% sequence homology. Forty per cent of the α-gliadin transcripts clustered with A 
genomic sequences and were attributed to locus Gli-A2, 35% originated from Gli-D2 
and only 25% came from Gli-B2 (Figure. S1). After tracing all non-synonymous DNA 
polymorphisms 83 different transcript contigs were obtained for the 3’ region of the 
gene that each contained at least four sequence equivalents. This indicates a high 
sequence diversity among expressed α-gliadin sequences in these 11 T. aestivum L. 
varieties. 
 
Table 1. Amino acid sequences of α-gliadin derived peptides. 
 Immune response Restriction element Core-Sequence 
DQ2-Glia-α1 Adaptive HLA-DQ2 P{F/Y}PQPQLPY 
DQ2-Glia-α2 Adaptive HLA-DQ2 PQPQLPYPQ 
DQ2-Glia-α3 Adaptive HLA-DQ2 FRPQQPYPQ 
DQ8-Glia-α1 Adaptive HLA-DQ8 QGSFQPSQQ 
P31-43 Innate not applicable PGQQQPFPPQQPY 
Five antigenic peptides derived from α-gliadins are known to be involved in celiac decease. For 
the peptides that can provoke an adaptive immune response in CD patients (HLA-DQ2 restricted 
or HLA-DQ8 restricted) the minimal 9-mer “canonical” epitope cores are shown. One peptide, 
p31-43, is known to be involved in an innate immune response observed in CD. For each of the 
epitopes is specified the name, which immune response it evokes, the restriction element and the 
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Variants of T cell stimulatory and innate stimulatory sequences 
The N-terminal region of α-gliadins contains the p31-43 epitope implicated in the innate 
immune response, and the immunodominant DQ2-Glia-α1 and DQ2-Glia-α2 epitopes as 
well as the DQ2-Glia-α3 T cell epitope. The carboxyl-terminal part encodes the immu-
nodominant DQ8-Glia-α1 T cell epitope (Table 1). To obtain information on the immuno-
genic potential of the various α-gliadins, the translated amino acid sequences for each 
locus were checked for the presence of canonical T cell epitopes and variants thereof. 
Table 2-5 present the most frequently expressed epitope variants (>5 transcripts each). 
 
Table 2. HLA-DQ2-Glia-α1 epitope variants expressed in bread wheat. 
 Gli-A2 Gli-B2 Gli-D2 N 
PFPQPQLPY 466  520 986 
PYPQPQLPY   93 93 
PFLQPQLPY 106   106 
PFSQPQLPY 94   94 
PFPQPQLSY 7  54 61 
PFPHPQLPY   29 29 
PFPQAQLPY   6 6 
Total 673  702 1375 
Expressed variants of the DQ2-Glia-α1 epitope represented by ≥5 transcripts and the number of 
transcripts per epitope variants per chromosomal locus (Gli-A2, Gli-B2 or Gli-D2). N= total tran-
script count per variant. In bold: amino acid variation. 
 
Table 3. DQ2-Glia-α2 epitope variants expressed in bread wheat. 
 Gli-A2 Gli-B2 Gli-D2 N 
PQPQLPYPQ   607 607 
PQPQLPYSQ 431   431 
FPPQLPYPQ  382  382 
LQPQLPYSQ 106   106 
FLPQLPYPQ  31  31 
SQPQLPYSQ 85   85 
PQPQLSYPQ   54 54 
PQPHLPYPQ   30 30 
PHPQLPYPQ   29 29 
PQPQLSYSQ 7   7 
PQAQLPYSQ   6 6 
PQPQPQYPQ  6  6 
Total 629 419 726 1774 
Expressed variants of the DQ2-Glia-α2 epitope represented by ≥5 transcripts and the number of 
transcripts per epitope variants per chromosomal locus (Gli-A2, Gli-B2 or Gli-D2). N= total tran-
script count per variant. In bold: amino acid variation. 
 
We observed that canonical DQ2-Glia-α1 (Table 2) and DQ2-Glia-α3 epitopes  (Table 4) 
were only present in Gli-A2 and Gli-D2 transcripts and that the canonical DQ2-Glia-α2 
motif (Table 3) was unique for Gli-D2 transcripts (72% of all Gli-D2 transcripts contained 
at least one DQ2-Glia-α2 epitope core). DQ8-Glia-α1 canonical epitopes were present in 
Gli-D2 and Gli-B2 transcripts only (Table 5). The canonical p31-43 motif was not restrict-
ed to transcripts from a specific locus and was found in transcripts from all α-gliadin loci.  
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Table 4. DQ2-Glia-α3 epitope variants expressed in bread wheat 
 Gli-A2 Gli-B2 Gli-D2 N 
FRPQQPYPQ 650  449 1099 
FPPQQPYPQ 732 687 606 2025 
FPSQQPYPQ  179 8 187 
FRPQQSYPQ   157 157 
FPPQQPYPH  148  148 
FPAQQPYPQ  56  56 
FPPQQSYPQ  18  18 
FPGQQPYPQ  20  20 
FQPQQPYPQ 13   13 
FLPQQPYPQ   8 8 
FRPQQQYPQ   6 6 
Total 1395  1108  1234 3737 
Expressed variants of the DQ2-Glia-α3 epitope represented by ≥5 transcripts and the number of 
transcripts per epitope variants per chromosomal locus (Gli-A2, Gli-B2 or Gli-D2). In italics: DQ2-
Glia-α3 variants located on the position of the innate responsive element, p31-43. N= total tran-
script count per variant. In bold: amino acid variation. 
 
Table 5. DQ8-Glia-α1 epitope variants expressed in bread wheat. 
 Gli-A2 Gli-B2 Gli-D2 N 
QGSFQPSQQN  186 381 567 
QGSFRPSQQN 409   409 
QGFFQPSQQN   114 114 
QGSFRPFQQN 103   103 
QVSFQPSQLN  112  112 
QGSFQSSQQN  111  111 
QGSFQPFQQN  4 27 31 
QGFFQPFQQN   6 6 
Total 512 413 528 1453 
Expressed variants of the DQ8-Glia-α1 epitope, represented by ≥5 transcripts and the number of 
transcripts per epitope variants per chromosomal locus (Gli-A2, Gli-B2 or Gli-D2). N= total tran-
script count per variant. In bold: amino acid variation 
 
In addition to the canonical epitope motifs, a large series of sequence variants with 
one or two amino acid substitutions were detected (Table 2-5). The large majority of 
the Gli-B2 gliadins contained sequence variants of the DQ2-Glia-α1, DQ2-Glia-α2, and 
DQ2-Glia-α3 epitopes with two amino acid substitutions. Furthermore, Gli-A2 tran-
scripts harbored a proline to serine substitution at position 8 (p8) of the DQ2-Glia-α2 
epitope and a sequence variant (QGSFRP(S/F)QQN, amino acid substitution in bold) of 
the  DQ8-Glia-α1 epitopes. Importantly, the 33-mer peptide (LQLQPFPQPQLPYPQ-
PQLPYPQPQLPYPQPQPF) that is highly resistant to degradation in the gastrointestinal 
tract and contains six overlapping DQ2-Glia-α1 and DQ2-Glia-α2 epitopes, conferring 
superior T cell stimulatory properties [13], was only observed in a subset of the α-
gliadins from the Gli-D2 locus and never in the α-gliadins from the Gli-A2 and Gli-B2 
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Table 6. T cell proliferation and HLA-DQ2 binding capacity of DQ2-Glia-α variants. 
  
No 
Peptide locus IC50 
DQ2-Glia-α1 
Glia-α1 




T cell clone 
1 QLQPFPQPELPYPQPE Gli-D2 5 + 18 + 
2 QLQPFPQPELPYPQPQ Gli-D2 5 + 34 + 
3 QLQPFPQAELPYSQPQ Gli-D2 8 ± 11 - 
4 QLQPFPQPELSYPQPQ Gli-D2 12 - 24 - 
5 QLQRPFPQPELPYPQPE Gli-D2 14 ± 19 + 
6 QLQPFPQPELPYTH Gli-D2 21 + 21 - 
7 QLQPFPHPELPYPQPQ Gli-D2 42 + 41 ± 
8 QLQPFSQPELPYSQPQ Gli-A2 7 ± 32 - 
9 QLQPFPQPELPYSQPQ Gli-A2 57 + 41 - 
10 QLQPFPQPELPYSQPE Gli-A2 67 + 24 - 
11 QPQPFL-PELPYPQPE Gli-B2 4 - 4 ± 
12 QPQPF-QPELPYPQPE Gli-B2 8 - 8 + 
13 QPQEFP-PELPYPQPE Gli-B2 45 - 45 - 
14 QPQQFP-PELPYPQPE Gli-B2 86 - 86 - 
15 QPQPFP-PELPYPQTQP Gli-B2 nd - nd - 
   IC50  
DQ2-Glia-α3 
Glia-α3 
T cell clone 
  
16 QPFRPEQPYPQPQPQ Gli-A2/D2 35 +   
7 QPFPPEQPYPQPQPQ Gli-A2/D2/ B2 3080 -   
   IC50            
DQ8-Glia-α1 
DQ8-Glia-α1                 
T cell clone 
  
18 LGEGSFQPSQENP Gli-D2/B2 16 +   
19 LGEGSFRPSQENP Gli-A2 33 -   
20 LGEGFFQPSQENP Gli-D2 nd -   
Variants of the DQ2-Glia-α1 and DQ2-Glia-α2 epitopes as encoded by the α-gliadin transcriptome were 
synthesized as deamidated 14- to 17-mer peptides (column 1, underlined: DQ2-Glia-α1/α2 epitope 
region) and tested for stimulation of DQ2-Glia-α1 and DQ2-Glia-α2 specific T cell clones in a prolifera-
tion assay. ± = 100 times reduced T cell stimulation compared to the ‘canonical’ epitope; - = 1000 times 
reduced T cell stimulation compared to the ‘canonical’ epitope. For each epitope shorter versions of the 
peptide variant, including the putative epitope core flanked by at least two amino acids, were tested in 
a cell free in vitro peptide binding assay for binding to HLA-DQ2 antigen presenting cells (lysates from 
HLA-DR3/DQ2 positive EBV-transfored B-cells). IC50 DQ2-Glia-α1/α2=mean value of the half maximal 
inhibitory concentration (IC50) returned by the binding assays for respectively DQ2-Glia-α1 and DQ2-
Glia-α2 epitope variants. IC50 values were calculated based on the observed competition between the 
tested peptides and biotin-labelled indicator peptides and indicate the concentration of the tested 
peptide required for half maximal inhibition of the binding of the indicator peptide. 
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T cell stimulatory capacity of α-gliadin derived peptides 
Several of the amino acid variants that we found in the α-gliadin transcriptome have 
never been described before while some have been described but were never tested 
for their T cell stimulatory capacity. In order to determine which variants are capable 
of inducing T cell responses, the DQ2-Glia-α1, DQ2-Glia-α2, DQ2-Glia-α3, and DQ8-
Glia-α1 variants were synthesized as 15- or 16-mer peptides and tested for their capac-
ity to bind to HLA-DQ2 and induce in vitro proliferation of HLA DQ2- or DQ8-restricted 
T cell clones. 
DQ2-Glia-α1 variants: virtually all peptides that carry the canonical 9-mer Glia-α1 
epitope core P1{F/Y}2P3Q4P5E6L7P8Y9 (in which the glutamic acid at p6 is introduced by 
TG2-deamidation of the original glutamine) were able to stimulate DQ2-Glia-α1 T cells. 
Only an arginine residue at the position preceding the epitope core diminished T cell 
stimulation. In the core sequence, several amino acid substitutions diminished or abol-
ished the T cell stimulatory capacity, such as a proline to serine substitution at p3 or p8 
and a proline to alanine substitution at p5 (Table 6, no. 3). Peptides in which an amino 
acid was deleted at p3 or p4 were not causing any proliferation of the T cells. Striking-
ly, such safe peptides are all from locus Gli-B2 (Table 6, Figure S3). 
DQ2-Glia-α2 variants: full responses of DQ2-Glia-α2 T cells were only observed against 
peptides that carry the core P/F1Q2P3E4L5P6Y7P8Q9 . A deletion of the glutamine at p2, 
indicative for α-gliadins from locus Gli-B2, or substitution of this glutamine by histidine 
diminished or abolished the stimulatory capacity. Furthermore, a single substitution of 
the proline for an serine residue at either p6 or p8 abolished the T cell stimulating 
capacity. The latter substitution is found in α-gliadins from locus Gli-A2 (Table 6).  
DQ2-Glia-α3 variants: also for this epitope several amino acid substitutions were found 
to destroy T cell stimulatory capacity, including an arginine to proline substitution at 
p2, which is found in α-gliadins from Gli-B2 (Table 6). 
DQ8-Glia-α1 variants: while several amino acid substitutions were found to influence T 
cell recognition of the canonical sequence Q1G2S3F4Q5P6S7Q8Q9, a single serine to phe-
nylalanine substitution at p3 and a single glutamine to arginine substitution at p5 were 
found to completely destroy T cell stimulatory properties (Table 6). While the former T 
cell stimulatory variants are found in α-gliadins from Gli-D2 and Gli-B2, the glutamine 
to arginine variants are from Gli-A2 (Table 5, Figure S2).  
Thus, the α-gliadins encoded by Gli-A2 of bread wheat are marked with a specific sin-
gle amino acid substitution (P to S at p8) and lack the capacity to stimulate Glia-α2 T 
cell clones, whereas α-gliadins encoded by Gli-B2 carry a deletion that prevents Glia-α1 
T cell clone stimulation. Alpha-gliadins with the two intact epitopes, Glia-α1 and Glia-
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T cell stimulatory capacity of diploid wheat accessions 
Previously, differential reactivity of α-gliadin specific T cell clones against gluten ex-
tracts from diploid wheat accessions has been reported [18,19]. In order to link such 
differential reactivity to the presence of specific epitope variants, a panel of diploid 
wheat accessions containing either the A, S or D genome was tested for their reactivity 
of an α-gliadin specific monoclonal antibody (mAb) and T cells.  
Pepsin-trypsin digests of gluten extracts from kernels of 29 diploid Triticum and 
Aegilops accessions were prepared and tested in a competition ELISA with a mAb spe-
cific for a sequence partially overlapping with the DQ2-Glia-α1 and DQ2-Glia-α2 
epitopes (Figure 1A) and, after treatment with TG2, with T cell clones specific for either 
the DQ2-Glia-α1 and DQ2-Glia-α2 epitope (Figures 1B and 1C). The results indicate that 
the mAb reacts strongly with all extracts except three derived from diploids expressing 
the S genome (Figure 1A). Similarly, and in agreement with previous results [18], ex-
tracts from A, S and D origin were capable of stimulating the DQ2-Glia-α1 specific T cell 
clone (Figure 1B) while the extracts of the diploids expressing the A genome failed to 
stimulate the DQ2-Glia-α2 specific T cell clone (Figure 1C). 
Based on our observation that the α-gliadins expressed from locus Gli-A2 of the T. 
aestivum A genome carry a variant DQ2-Glia-α2 epitope in which the proline at p8 has 
been replaced by a serine, and our experimental result that introducing this substitu-
tion in a peptide leads to loss of DQ2-Glia-α2 T cell stimulatory properties (Table 6), we 
wanted to determine if this amino acid substitution was indeed the cause of loss of 
immunogenicity. For this purpose we sequenced the α-gliadin locus of three diploid 
wheat (T. monococcum, A genome) accessions. In agreement with the results from 
hexaploid wheat transcripts (Figure S2) we observed that the α-gliadin transcripts from 
T. monococcum contain only a single form of DQ2-Glia-α1 and DQ2-Glia-α2. Moreover, 
in the DQ2-Glia-α2 epitope the proline at p8 was consistently replaced by a serine 
(Table S1). Together these results establish that this naturally occurring single amino 
acid substitution is sufficient to completely eliminate the T cell stimulatory properties 
of the DQ2-Glia-α2 epitope in gluten. 
Differential reactivity of the DQ2-Glia-α3 specific T cells towards the extracts of 
the diploids correlated with an arginine to proline replacement at p2 in α-gliadins de-
rived from the S-genome, FRPQQPYPQ→ FPPQQPYPQ (Table 6). 
 
Elimination of α-gliadin toxicity by a naturally occurring single amino acid 
substitution 
The large majority of known antigenic peptides derived from wheat gluten, as well as 
homologous peptides derived from the hordeins from barley and the secalins from rye, 
contain a proline at p8 [24]. Based on our observation that a single proline to serine 
substitution at p8 induced unresponsiveness of DQ2-Glia-α2 specific T cells and the 
previous observation that a similar substitution at p8 of the DQ2-Glia-α1 epitope in-
duced T cell unresponsiveness (Table 6; peptide no.4), we investigated if a similar sub-
stitution would also eliminate the antigenic properties of the DQ2-Glia-α3 epitope. 
Wild type versions of the DQ2-Glia-α1, -α2 and -α3 epitopes as well as versions in 
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Although T cell responses to peptides derived from α-, γ- and ω-gliadins as well as from 
HMW- and LMW-glutenins have been described, various studies have indicated that 
the α-gliadins are among the most immunogenic regarding CD [8-10,13,25]. A crucial 
step towards the elimination of gluten toxicity would thus be the elimination of T cell 
stimulatory α-gliadin sequences. Our extensive genetic analysis of over 3000 α-gliadin 
transcripts from different bread wheat accessions showed a high heterogeneity of the 
α-gliadins genes and considerable differences in the number of T cell stimulatory se-
quences encoded by the various α-gliadin genes. We identified three major factors 
determining these differences: i) the length of tandem repeats of antigenic sequences; 
ii) natural amino acid substitutions that affect the antigenicity of T cell epitopes, and 
iii) amino acid deletions that eliminate the antigenicity of T cell epitopes. 
The α-gliadins from locus Gli-D2 generally encode several copies of both the DQ2-
Glia-α1 and DQ2-Glia-α2 epitopes in addition to the DQ2-Glia-α3 and DQ8-Glia-α1 
epitopes, Gli-A2 genes usually encode only the DQ2-Glia-α1 and DQ2-Glia-α3 epitopes 
while the Gli-B2 genes encode no or at most one DQ2-Glia-α1 epitope, next to the 
DQ8-Glia-α1 epitopes. The 33-mer sequence with 6 T cell stimulatory sequences [13] 
was only found in a minority of the α-gliadins analyzed, all of which are expressed from 
Gli-D2. Many natural occuring amino acid substitutions affecting the antigenicity of the 
canonical α-gliadin peptides were identified. Typical examples are the proline to serine 
substitution at p8 in the DQ2-Glia-α2 epitope and the arginine to proline substitution 
at p2 in the DQ2-Glia-α3 epitope, that both completely eliminate the T cell stimulatory 
properties of these peptides.  
The analysis of gluten extracts from the diploid wheat varieties underscores these 
observations and provides a molecular basis for the previous observation that A-
genome diploid T. monococcum varieties lack the DQ2-Glia-α2 epitope [18]. All α-
gliadins from this genome encode an altered version of the DQ2-Glia-α2 epitope with a 
serine at p8 that fails to induce T cell responses. We observed that a similar substitu-
tion eliminates the T cell stimulatory properties of the DQ2-Glia-α1 and DQ2-Glia-α3 
epitopes. The more variable reaction pattern of T-cells and antibodies towards gluten 
extracts of the S-genomes reflects the higher level of genetic variation in these out-
crossing species. These α-gliadins contain another variant of the DQ2-Glia-α1 and DQ2-
Glia-α2 region that does not incude the A-genome specific serine at p8. Furthermore, 
amino acid deletions in the canonical α-gliadin peptides prohibit binding to HLA-DQ2 
and hence T cell recognition. A typical example is the deletion of the glutamine at p4 in 
the DQ2-Glia-α1 epitope which generates a peptide that no longer binds to HLA-DQ2, 
presumably due to defective docking of the anchor residues into their respective pock-
ets in the HLA-DQ2 molecule. Our results confirm previous observations [18, 19] that 
the α-gliadin locus Gli-D2 encodes the most toxic α-gliadins while substantially less 
toxicity is associated with those from Gli-A2 and Gli-B2, but also provide the molecular 
basis for these differences.  
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Unfortunately, due to the complexity of both the Gli-2 gene family and the wheat 
genome, it will be a difficult task to generate tetraploid pasta and hexaploid bread 
wheat that is entirely safe for consumption by all CD patients by conventional breeding 
methods. Our results now provide a rationale for an alternative approach as we 
demonstrate that by the introduction of naturally occurring amino acid substitutions 
the toxicity of all four T cell epitopes in α-gliadins can be eliminated. Using novel 
methods such as zinc finger nucleases [26-28] we can introduce the underlying SNPs as 
specific mutations into the α-gliadin genes of wheat to eliminate toxicity completely. 
Technically this will not be easy, but our results indicate precisely the three comple-
mentary sets of actions that need to be performed. 
i) In the Gli-B2-derived α-gliadins analyzed, none of the DQ2 epitopes are present 
due to a single amino acid deletion in the region encoding the DQ2-Glia-α1 and DQ2-
Glia-α2 epitopes, which generates a peptide that has decreased binding affinity for 
HLA-DQ2 and is no longer recognized by T cells. Therefore, a single amino acid substi-
tution in the DQ2-Glia-α3 epitope will result in a peptide that has completely lost HLA-
DQ2 binding properties and T cell stimulatory properties. To eliminate the remaining 
DQ8-Glia-α1 epitope in some Gli-B2 α-gliadins, a single glutamine to arginine substitu-
tion, which naturally occurs in the α-gliadins from the A-genome, would suffice. Such a 
minimally genetically modified B-genome α-gliadin gene would thus no longer encode 
any T cell stimulatory peptides. Moreover, by starting with an α-gliadin gene in which 
the sequence of the p31-43 peptide is naturally altered (for example the gene encod-
ing protein no. 9 in SI 2), the chance of innate immune stimulation by a protein derived 
from such a gene would also be minimized. 
ii) For Gli-A2 α-gliadins, the approach to eliminate toxicity would be to introduce 
two proline to serine substitutions at p8 in the DQ2-Glia-α1 and DQ2-Glia-α3 epitopes 
present. As these α-gliadins genes encode a shorter version of the immunodominant 
33-mer in which the DQ2-Glia-α-2 epitope is already non-functional, and contain a 
version of the DQ8-Glia-α1 epitope that has no T cell stimulatory properties, these two 
substitutions would completely remove toxicity in proteins encoded by such modified 
genes.  
iii) Regarding the Gli-D2 α-gliadins, we found that the proline to serine substitu-
tions at p8 completely abrogated the in vitro T cell stimulatory properties of the 33-
mer peptide and of an elongated version of the 33-mer that also encodes the DQ2-
Glia-α3 epitope. This result underscores our previous observation that most T cell 
stimulatory gluten peptides have a proline at p8 [24]. However, to render α-gliadins 
from the D-genome non-toxic, up to seven substitutions need to be introduced in a 
single gene. 
An alternative approach is to design safe α-gliadin genes that can subsequently be 
introduced into celiac disease safe cereals such as rice or maize, for the production of 
gluten proteins. As such modified proteins will be very similar to existing α-gliadins 
they will most likely have indistinguishable technological properties. Thus, such gluten 
proteins could enhance the baking properties of these cereal crops, or they could be 
extracted from these crops and used as an ingredient to generate novel high quality 
foods for celiac disease patients. For the generation of high quality cereals that can 
replace wheat-based products the simple introduction of detoxified α-gliadins is un-
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likely to be sufficient, as baking quality is mostly determined by the HMW and LMW 
glutenin proteins. Therefore, additional studies will have to investigate how other 
gluten proteins can be detoxified as there is substantial evidence that these contain T 
cell stimulatory peptides as well. In previous studies we provided evidence that such 
epitopes can be found in the γ-gliadins as well as in the LMW- and HMW-glutenins [11, 
12] and others have extended these observations [14, 25]. In particular, we found that 
T cell responses to LMW-glutenins were found in children while these are much less 
frequent in adults [12, 25]. Moreover, in a recent study a highly antigenic ω-gliadin 
peptide was described [25] that is identical to an antigenic hordein-derived peptide 
reported by us earlier [20]. In essence this hordein/omega peptide is a sequence vari-
ant of the DQ2-Glia-α1 peptide and also carries a proline at the p8 position [20]. It is 
therefore feasible that the toxicity of this peptide can be eliminated by a proline to 
serine substitution at p8 as well. Preliminary results show that amino acid substitutions 
similar to those that destroy the T cell stimulatory properties in α-gliadins might also 
be effective for γ-gliadin derived epitopes  (Salentijn et al, in prep), but it is likely that 
for the LMW- and HMW-glutenins other approaches will be required. This will be the 
subject of further studies. 
In conclusion, we have demonstrated that by utilizing naturally occurring amino 
acid substitutions the toxicity of the four T cell epitopes in α-gliadins can be eliminat-
ed. Such modified proteins will most likely display indistinguishable technological 
properties. Thus, our results provide a rational approach to eliminate CD related toxici-
ty from α-gliadins, which represents a first but crucial step towards the realization of 
safe gluten containing food products for CD patients.  
 
 
MATERIAL AND METHODS 
 
Analysis of α-gliadin transcripts from diploid wheat varieties 
T. monococcum accessions CGN10500, CGN12035 and CGN10555 (CGN, Wageningen, 
The Netherlands) were used for cloning and sequencing of α-gliadin transcripts. Plants 
were grown under greenhouse conditions. Developing green kernels of single plants 
were harvested and used for RNA isolation according to Doyle and Doyle [29] but with 
1% (w/v) poly-(vinylpyrrolidone)-10 in the extraction buffer. For the production of first 
strand cDNA 1 μg of total RNA was treated with DNAse I (Invitrogen, amplification 
grade; 18068-015) followed by RT PCR (Invitrogen SuperScript III First-Strand Synthesis 
System for RT-PCR; 18080-051) using random hexamer primers in a final reaction vol-
ume of 20 μl. Primers specific for α-gliadin genes, located on the conserved sequences 
at the 5' and 3' end of the coding region of the α-gliadin, were used to amplify α-
gliadin transcripts from the cDNA samples (αF1: 5’-atgaaRaCmtttcYcatc and α5R: 5’-
gttagtaccgaNgatgcc). The PCR conditions: 5 min. at 94°C, 30 cycles (94°C for 1 min., 
49°C for 1 min. and 72°C for 2 min), 72°C for 10 min, 25 μl reaction volume. The PCR 
products were cloned and sequenced.  
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Characterization of expressed α-gliadin sequences 
Over 3200 T. aestivum expressed sequence tags (ESTs) and mRNAs designated as α-
gliadin or α/β-gliadin were downloaded from the NCBI UniGene library (Ta.15268, 
Ta.23792, Ta.24084, Ta.25210, Ta.27702, Ta.28482) (http://www.ncbi.nml.nih.gov/ 
UniGene) on 13 April 2007. The sequences were from T. aestivum libraries of various 
tissues, treatments and cultivars (Chinese Spring 34.2%; Glenlea 20.8%; Cheyenne 
10.4%; Recital 7.8%; Mercia 7.2%; unknown cultivar 8.9%; Wyuna 3.2%; HiLine 2.9%; 
Butte 86, 2.4%; Hartog 1.5%; Soleil 0.6%; Nostar 0.1%; Novobirskaya 67, 0.1%). The 
DNA sequences were aligned using the SeqMan II (DNAstar) and first assembled at a 
minimum match percentage of 60%, gap lengths 3200, maximum match size 50bp. 
BLAST analysis of the contigs was performed to verify the α-gliadin identity of the con-
tigs and short (<100bp) and bad sequences were discarded. The transcript contigs of 
≥60% homologous sequences were trimmed up to the start and stop codons. Next, the 
sequences were reassembled at 90% homology, which resulted in 55 α-gliadin tran-
script contigs containing 1 to 475 sequences. The 3’ end was covered by 50 contigs 
(2911 transcripts) whereas the 5’ end was present in 30 contigs (2753 transcripts). The 
consensus of these contigs were saved in separate files and used for phylogenetic 
studies to deduce the genome of origin of the sequences in each contig. 
 
Phylogenic analysis 
With the aim to deduce the locus, Gli-A2, Gli-B2 or Gli-D2, from which the transcripts 
were expressed, the 55 α-gliadin EST consensus nucleotide sequences obtained from 
clustering, were aligned using Clustal W, MEGA 4 [30], together with 56 genomic DNA 
sequences of known origin, i.e. derived from the diploid wheat species T. monococcum 
(A genome), T. speltoides (S genome) and Aegilops tauschii (D genome) [18] and DNA 
sequences that were previously assigned to a locus [31]. The sequences that covered 
the 5’ region of the α-gliadin sequences were trimmed up to the start and up to nucle-
otides coding for the conserved amino acid motif PIS, located just in front of the first 
glutamine repeat, to cover the same region and subsequently used to generate a 
Neighbor-Joining tree (bootstrap test of 1000 replicates, pairwise deletion of gaps and 
missing data, Kimura 2-parameter, Substitutions to Include Transitions + Transversions; 
Pattern among Lineages Homogeneous, Uniform rates among sites, number of sites= 
750, in MEGA 4) (Figure S1). 
 
Sequence variation in epitope regions  
To analyze all sequence variation, the 55 α-gliadin EST contigs, now assigned to a spe-
cific chromosome, were reassembled one by one at 99-100% match (SeqMan II, La-
sergene, DNAstar). This yielded 717 different allelic variants. The consensus nucleotide 
sequences were translated (MEGA 4) and explored for epitopes and surrounding se-
quence regions using a text explorer program (PatternResearch, in house developed) 







T cell clones, T cell proliferation and HLA-DQ2 binding assays 
Gluten specific T cell clones were generated from small intestinal biopsies of celiac 
disease patients as described before [8,11,12]. All patients signed an informed consent 
form which was approved by the hospital ethics committee. Proliferation assays were 
performed in triplicate in 150 μl Iscove’s Modified Dulbecco’s Medium (Bio Whittaker, 
Verviers, Belgium) with 10% pooled normal human serum in 96 well flat-bottom plates 
using 2x104 gluten specific T cells stimulated with 105 irradiated HLA-DQ2-matched 
allogeneic peripheral blood mononuclear cells (3000 rad) in the presence or absence of 
antigen (1-10 μg/ml) [8, 11, 12]. After 2 days 
3
H-thymidine (0.5 μCi/well) was added to 
the cultures, and 18-20 hours thereafter the cells were harvested. 
3
H-thymidine incor-
poration in the T cell DNA was determined with a liquid scintillation counter (1205 
Betaplate Liquid Scintillation Counter, LKB Instruments, Gaithersburg, MD). A binding 
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Celiac disease (CD) is a chronic inflammatory disease affecting the small intestinal 
mucosa. The causative agents have been identified as gluten proteins from wheat, 
barley and rye, and the only available treatment for CD patients is a lifelong gluten-
free diet. Non-gluten containing cereals would be a valuable contribution to the glu-
ten-free diet. In this respect, oats are a good choice. However, commercial lots of oat 
flakes and flour frequently are contaminated with wheat, barley and rye, and two 
studies have reported that some peptides derived from the gluten-like avenin storage 
proteins of oat can trigger an immune response in some CD patients. In the present 
study we have initiated the investigation whether all oat varieties contain similar 
amounts of potentially harmful sequences by biochemical and immunological meth-
ods. We confirm that commercial oat preparations are contaminated with other cere-
als that contain gluten or gluten-like proteins. Moreover, our results demonstrate that 
contamination-free oat varieties differ in their capacity to stimulate an avenin-
sensitive gamma-gliadin specific T cell line derived from a patient with CD, indicative 
for differences in the two known avenin epitopes among oat varieties, implying that 












Celiac disease (CD) is a food intolerance that affects approximately 1% of the popula-
tion (10). Typical symptoms include diarrhea, abdominal distention and pain. Extra-
intestinal manifestations like anemia, infertility, growth deficiency and neurological 
symptoms can also be present (4). 
CD is an immune mediated disease in which protein fragments from wheat, barley 
and rye provoke an inappropriate immune response. It is well established that the 
disease almost only develops in HLA-DQ2 and/or -DQ8 positive individuals (11, 19). 
HLA-DQ2 and -DQ8 are HLA-class II molecules involved in binding peptides derived 
from exogenous proteins and “presenting” these peptides to the T cells of the immune 
system (9). Both HLA-DQ2 and -DQ8 can bind gluten-derived peptides, particularly 
after enzymatic modification by the enzyme tissue transglutaminase (tTG) (2), which 
introduces negative charges in gluten peptides required for efficient binding to the 
HLA-molecules. Upon binding, the HLA-DQ-gluten peptide complexes can trigger in-
flammatory T cell responses which ultimately lead to disease (14, 28). As such gluten 
specific T cells can only be isolated from the small intestine of CD patients, these adap-
tive immune responses are a critical factor in disease pathogenesis. 
Upon withdrawal of gluten the inflammation subdues and patients can lead a 
normal life as long as they stick to a lifelong gluten-free diet, thus devoid of any prod-
ucts prepared from wheat, barley and rye. Food products based on gluten-containing 
cereals, however, form an important component of the human diet and celiac patients 
need alternative cereals that substitute this source of fiber and nutrients. One of the 
possible candidates is oat but this is still controversial as contradictory reports have 
appeared concerning the safety of oat for CD patients. Several studies have docu-
mented that >99% of CD patients can safely consume oat (6, 7, 15), and on that basis 
non-contaminated (‘pure’) oat is now considered as gluten-free in EC-regulation 
41/2009. 
However, two studies have found CD patients that do not tolerate contamination-
free oats: three CD patients developed intestinal inflammation upon oat exposure (1) 
and one developed partial villous atrophy (8). It has also been demonstrated that glu-
ten-reactive T cells from some CD patients can also respond to avenin-derived pep-
tides (24). Also, an avenin specific T cell line has been isolated from the biopsy of a 
celiac patient which developed villous atrophy during an oat-containing, but otherwise 
standard gluten-free diet (1). These results thus indicate that oat may not be com-
pletely harmless to all patients. Furthermore, contamination of oats with other cereals, 
due to the shared use of equipment for transportation and fabrication for both oat and 
other cereals, is quite frequent as was previously reported (3, 5). Therefore, the toxici-
ty of oat can be due to both contamination and intrinsic toxicity but the result is the 
same: it leads to uncertainty about introduction of oat in the gluten-free diet, especial-
ly in those countries where oat is a not-frequently consumed food product. 
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The present study is focused on the characterization of this potential intrinsic im-




MATERIALS AND METHODS  
 
Oat samples 
The grains of twenty-six oat varieties (1: Ascot, 2: Astor, 3: Charming, 4: Charmoise, 5: 
Dalguise, 6: Dominik, 7: Fervente, 8: Firth, 9: Freddy, 10: Gambo, 11: Gele van Tim-
mermans, 12: Gerald, 13: Gigant, 14: Leanda, 15: Mansholt III, 16: Markant, 17: Mus-
tang, 18: Ouderwetse Zeeuwse Partij, 19: Panache de Roye, 20: Powys, 21: Sang, 22: 
Troshaver uit Besel, 23: Valiant, 24: Wodan, 25: Zandster, 26: Zwarte President) were 
used in this study. All varieties were obtained from CGN (Wageningen, The Nether-
lands) and the grains were washed with 60% aqueous ethanol and dried over-night to 
remove any trace of other cereals before grinding in a coffee mill to obtain a fine ho-
mogenized powder. As contamination of oats by other cereals is well documented 
(3, 5), we analyzed eight varieties for possible contamination using a sandwich R5 ELI-
SA kit (Ingezim
®
 Gluten, Ingenasa, Spain) and a competition assay based on a specific 
mAb which recognizes the α20-gliadin epitope and homologous sequences from barley 
and rye (20). These varieties were Astor, Gele van Timmerman, Mansholt III, Mustang, 
Panache de Roye, Troshaver uit Besel, Wodan and Zwarte President. All samples were 
found to be contamination free by both methods (< 1.5 mg/kg for the R5 method and 
< 25 μg/kg for the α20-gliadin epitope specific competition assay). 
 
Preparation of protein fractions from oat varieties 
Prolamins were extracted from the oat samples using 60% (v/v) ethanol as described 
before (3). Trypsin/pepsin digests were prepared as follows: 0.5 g of oat sample was 
solubilized in 4 mL of 1 mol/L acetic acid and boiled for 15 minutes. After cooling to 
room temperature (RT) 2.5 mg of pepsin was added and the mixture was incubated for 
4 hours at 37° C. Subsequently the pH was adjusted to 7.8 with NaOH, followed by 
addition of 5 mg of trypsin. After incubation overnight at 37°C the samples were boiled 
for 15 minutes. For the next 48 hours the samples were dialyzed against water using 
dialysis tubing with a cutoff of 10 kDa. The dialyzed material was centrifuged and frac-
tionated over a 10 kDa membrane for removal of the enzymes and any remaining 
insoluble material. For the subsequent experiments the fractions smaller than 10 kDa 
were used. A control sample was prepared using a commercial available gliadin prepa-
ration. For the T-cell assay the pepsin/trypsin digests were treated with tissue 






T cell proliferation assays 
The presence of T cell stimulatory epitopes in the oat samples was determined using a 
T cell line isolated from a small intestinal biopsy of a celiac disease patient (24). Prolif-
eration experiments were performed in triplicate in 150 μL Iscove's Modified Dulbec-
co's Media (IMDM) with 10% normal human serum in 96-well flat-bottom plates using 
2x10
4 
gluten specific T cells stimulated with 10
5 
irradiated (3000 rad) HLA-DQ2 or -DQ8 
matched allogenic peripheral blood mononuclear cells (PBMCs) in the presence of or 
absence of the antigen (4 μg/well). After 2 days 0.5 μCi/well 
3
H-thymidine was added 
to the cultures and after 18-20 hours the cells were harvested and the 
3
H-tymidine 




Peptides were synthesized by standard Fmoc chemistry on a SyroII peptide synthesizer 
as described previously (20). The integrity of the peptides was checked by reversed-
phase HPLC and mass spectrometry. When required, biotin was introduced in the res-
in-bound peptides by a 2-h coupling with a 6-fold equimolar preactivating mixture of 
biotin and benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate. 
 
Protein analysis by 1D sodiumdodecyl sulfate poly-acrylamide gel electro-
phoresis (SDS-PAGE) and Western Blotting 
To determine the level of T cell stimulatory epitopes, 10 μL of the prolamin extracts 
were dried in a CHRIST ALPHA freeze-dryer (Salm en Kipp, Breukelen, The Nether-
lands), resuspended in 20 μL of protein sample buffer [62.5 mM Tris-HCl pH 6.8, 5% 
(v/v) glycerol, 2% (w/v) SDS, 0.0005% (w/v) bromophenol blue and 5% (v/v) β-
mercaptoethanol] and incubated for 5 min at 95ºC in a water bath. After that, the 
samples were spin down using a centrifuge and 20 μL supernatant was loaded into the 
wells of a 12.5% (w/v) SDS-PAGE gel. The proteins were visualized either directly using 
Imperial
™
 Protein Stain (Pierce, Rockford, IL) or transferred to polyvinylidene difluoride 
membranes (Bio-Rad, Hercules, CA). For the Western Blot analysis, the proteins were 
visualized with monoclonal antibodies (mAbs) specific for stimulatory T cell epitopes 
from α20-gliadin and Low Molecular Weight (LMW)-glutenin (12, 20, 21). 
 
Competition assay for the quantitative detection of a T cell stimulatory 
epitope  
The content of a T cell stimulatory epitope involved in celiac disease and present in 
α20-gliadin was determined using specific Enzyme-Linked ImmunoSorbent Assays 
(ELISAs). Maxisorb Immunoplates (Nunc, Copenhagen, Denmark) were coated over-
night at +4°C with 100 µL/well of 2-5 µg/mL mAb in Phosphate Buffered Saline (PBS; 
154 mmol/L NaCl and 1.4 mmol/L NaH2PO4/Na2HPO4; pH 7.5). The plates were washed 
(5 times) with 0.02% (v/v) Tween-20 in PBS and the residual binding sites on the plates 
were blocked for 30 min at RT with 150 µL/well of 2% (w/v) skim milk powder (Fluka, 
Zwijndrecht, The Netherlands) in PBS. After a washing step, the plates were incubated 
for 1 h at RT with 50 µL/well of different dilutions of the prolamin extracts with 0.1% 
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(v/w) Tween-20/0.2% (w/v) skim milk powder in PBS, mixed with another 50 µL/well of 
the biotinylated indicator peptide at a concentration of 0.002-10 µg/mL, also with 
0.1% (v/w) Tween-20/0.2% (w/v) skim milk powder in PBS. After this step, the plates 
were washed and incubated for 30 min at RT with an excess of streptavidin-conjugated 
horseradish peroxidase (Sigma Aldrich, Zwijndrecht, The Netherlands) diluted with 
0.2% (w/v) skim milk powder in PBS. After a washing step, bound peroxidase was visu-
alized by incubation for 30 min, at RT and darkness, with 100 µL/well of a solution of 
3,3',5,5'-tetramethylbenzidine (TMB; Sigma Aldrich). The color reaction was stopped 
by the addition of 100 µL/well of 2 M H2SO4. Finally, absorbance at 450 nm was read 
on a multiscan plate reader (Wallac, Turku, Finland). For quantification, the standard 
curve was made using a synthetic peptide containing the immuno-stimulatory celiac 
disease epitope, in a concentration range from 1 µg/mL to 1 ng/mL. The assays were 
repeated at least twice. 
 
Direct binding assay 
Direct binding assays were performed in a similar way as the competition assays for 
the quantitative detection of T-cell stimulatory epitopes (a20-gliadin and LMW-
glutenin). Maxisorb Immunoplates (Nunc, Copenhagen, Denmark) were coated over-
night at +4°C with 100 µL/well of the different peptides in a concentration range be-
tween 0.1 and 10 µg/mL in Phosphate Buffered Saline (PBS; 154 mmol/L NaCl and 1.4 
mmol/L NaH2PO4/Na2HPO4; pH 7.5). The plates were washed (5 times) with 0.02% (v/v) 
Tween-20 in PBS and the residual binding sites on the plates were blocked for 30 min 
at RT with 150 µL/well of 2% (w/v) skim milk powder (Fluka, Zwijndrecht, The Nether-
lands) in PBS. After a washing step, the plates were incubated for 1 h at RT with 100 
µL/well of the different mAbs at a concentration of 1.5 µg/mL with 0.1% (v/w) Tween-
20/0.2% (w/v) skim milk powder in PBS. After this step, the plates were washed and 
incubated for 30 min at RT with an excess of rat-anti-mouse horseradish peroxidase 
conjugated polyclonal antibodies (Sigma Aldrich) diluted with 0.2% (w/v) skim milk 
powder in PBS. 
 
In gel digestion and characterization of proteins by mass spectrometry 
The desired gel bands, isolated from an Imperial
™
 (Pierce, Rockford, IL) stained gel, 
were digested with chymotrypsin using the Proteineer DP digestion robot (Bruker, 
Bremen, Germany). The protocol supplied by the manufacturer was followed. Digested 
proteins were analyzed by mass spectrometry as described previously (23). Searches 
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the majority of oat samples contain epitopes that can stimulate the gamma
specific T cell line, largely similar to the stimulation by the control avenin peptides but 
less stron
found to hardly induce T cell proliferation, indicating that some varieties appear to 
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Figure 1.
Proliferation of a 
oat varieties and 4 synthetic peptides containing avenin 
with tTG and after measuring protein concentration identical amounts of the digests were used. 
The proliferative responses were measured by thymidine (
eration in the absence of 




24). We now used this T cell line to test for the presence of such peptides in the sele
   
 
i  i   
i i    
 i  .






g compared to stimulation with gliadin. However, several samples were 
feration assay using a gliadin specific T cell line known to recognize avenin epitopes.
 capacity in a T cell proliferation assay. The results demonstrate that 
gamma
n specific T cell line differentially responds to oat samples
rols we included four avenin
-
samples, control: proliferation in the presence of gliadin extracts, cpm: 
gliadin specific T cell line, in the presence of peptic/tryptic digests of 26 
(24
 
). Subsequently these samples were tested for T 
-gliadin specific T cell line isolated from a 
-derived peptides, two of which were 
epitopes. All samples were first treated 
3











mAbs can be useful to
in cereals. In a previous study we have characterized the reactivity of several of such 
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Since CD patients do not tolerate wheat, barley and rye, alternatives to substitute for 
these commonly used cereals are desirable. In this respect oat has been proven to be a 
good candidate, especially in the Nordic countries during the last decade 
introduction of o
not commonly consumed, is still controversial as oat contains gluten
are known to contain a few peptides that can stimulate T cells isolated from small 
intestinal biop
patients can tolerate an oat containing gluten
be a logical explanation for these seemingly contradictory find
ically more distantly related to wheat than barley and rye and this is reflected in seve
al key differences between the avenins of oat and the gluten and gluten
in the other cereals. First, the amount of avenins in oat
than that of gliadin in wheat (10% of the total protein content in oat, compared to 40
50% in wheat), as most storage proteins in oat are globulins. Second, avenins contain 
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less proline, the amino acid that contributes especially to the resistance of gluten to 
degradation in the gastrointestinal tract and that is crucial for the specific modification 
by the enzyme tTG that is linked to gluten toxicity (24). Hence, the potential of releas-
ing stimulatory peptides is much lower. Together this means that oat contains much 
fewer sequences that are harmful for CD patients, and these are less abundant and 
more easily degraded in the gastrointestinal tract. This combination likely contributes 
significantly to the observed tolerance of CD patients to oat. It also fits in the “thresh-
old model” in which a certain amount of exposure to immunogenic gluten peptides is 
tolerated while higher exposure leads to disease (24). Recent clinical data indicate that 
the addition of oat to a gluten-free diet can even result in more rapid intestinal im-
provement (Markku Mäki, personal communication, 2010). 
A specific problem with oat is contamination (3, 5). Also in the present study did 
we observe that commercially grinded oat flours were mostly contaminated with other 
cereals (data not shown). Such contaminated oat is not considered safe for consump-
tion by CD patients. This result underlines the importance of establishing a contamina-
tion-free oat chain for the production of suitable products for CD patients, which has 
been realized in Scandinavian countries and The Netherlands. 
For the determination of the relative immunogenicity of the oat samples we made 
use of a gamma-gliadin reactive T cell line that was previously shown to also respond 
to two avenin peptides (24). Such gluten-reactive T cells are isolated from the small 
intestine of celiac patients and thus are strongly linked with the disease. Such cells can 
give valuable information on the immunogenicity of a sample. In a series of experi-
ments with this T cell line we observed reproducible differences in the T cell stimulato-
ry capacity of the oat samples, indicative of differences in immunogenicity among 26 
oat varieties tested. This confirms and extends the results of Silano and collaborators, 
who observed differences among four oat varieties (17). A mAb originally raised 
against a LMW-glutenin peptide reacted with the oat preparations in Western Blot 
analysis, and mass spectrometric analysis demonstrated that the protein bands stained 
by the antibody contained, amongst others, two known immunogenic avenin peptides 
with sequence QQPFVQQQQPFVQQ and QYQPYPEQQQPFVQ. 
The oat varieties gave different signals with the LMW-glutenin antibody and the 
gamma-gliadin reactive T cell line. For example, variety Wodan (#24), which showed a 
strong reaction against the LMW-glutenin antibody, was also found to hardly induce T 
cell proliferation. By contrast, variety Mansholt III (#15), which gave a faint Western 
Blot reaction, proved to be very active in stimulating the gamma-gliadin specific T cell 
line. These observations could be explained by the different recognition patterns of 
both systems as the LMW-glutenin antibody reacted with the four avenin peptides 
tested while the gamma-gliadin specific T cell line only responded to two of them. 
Since the T cells are isolated from patients, their reactivity pattern probably best re-
flects the situation in vivo. 
In conclusion, our results show that most non-contaminated oat varieties contain 
avenin epitopes that are potentially harmful for a minority of the CD patient popula-
tion. Similarly to the situation in wheat (16, 21, 26, 27, 29), not all oat varieties display 
the same immunogenic profile, suggesting that the selection and breeding of oat varie-
ties that have a lower risk profile or have no risk at all for CD patients may be realistic. 
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A first step will be to clone and sequence avenin genes and cDNAs from oat varieties to 
analyze the presence of avenins with and without the epitopes. The T cell line will be 
useful to detect differences in the immunogenic potential of the oat material (flakes, 
flour, etc) derived from selected varieties. However, as true safety of cereals can only 
be ascertained when consumption by patients does not lead to clinical symptoms, 
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Celiac disease is caused by an immune response to gluten. As gluten proteins are pro-
line-rich they are resistant to enzymatic digestion in the gastrointestinal tract, a prop-
erty that likely contributes to the immunogenic nature of gluten. In this study we have 
determined the efficiency of gluten degradation by a post- proline cutting enzyme, 
prolyl endoprotease from Aspergillus niger (AN-PEP), in a dynamic system that closely 
mimics the human gastrointestinal tract (TIM-system). Two experiments were per-
formed. In the first, a slice of bread was processed in the TIM system with and without 
co-administration of AN-PEP. In the second, a standard fast food menu was used. Sam-
ples of the digesting meals were taken from the stomach, duodenum, jejunum and 
ileum compartments at time zero until four hours after the start of the experiment. In 
these samples the levels of immunogenic peptides from gliadins and glutenins were 
assessed by monoclonal antibody based competition assays, Western blot analysis and 
proliferation T-cell assays. AN-PEP accelerated the degradation of gluten in the stom-
ach compartment to such an extent that hardly any gluten reached the duodenum 
compartment. AN-PEP is capable of accelerating the degradation of gluten in a gastro-
intestinal system that closely mimics in vivo digestion. This implies that co-
administration of AN-PEP with a gluten containing meal might eliminate gluten toxici-











Celiac disease (CD) is a small intestinal disorder characterized by an abnormal immune 
response to gluten proteins. In CD patients ingestion of gluten evokes an immune re-
sponse in the small intestine that eventually results in T cell infiltration and flattening 
of the mucosa (1). Patients experience malabsorption, diarrhea and failure to thrive, 
leading to fatigue, osteoporosis and/or neurological symptoms. Gluten proteins are 
the storage proteins of wheat and contain high percentages of proline (20%) and glu-
tamine residues (38%).  Because of their unusual high content of proline (2) gluten is  
poorly degraded by enzymes present in the gastrointestinal tract (GI-tract). After in-
gestion, partially degraded gluten proteins reach the small intestine. Such fragments 
are good substrates for the enzyme tissue transglutaminase which can convert the 
amino acid glutamine in gluten into the negatively charged glutamic acid. These modi-
fied gluten fragments can bind with high affinity to the disease-associated HLA-DQ2 or 
HLA-DQ8 molecules and induce inflammatory T cell responses (3-6).  
Gluten is composed of two different protein families, the gliadins and glutenins. 
The gliadins can be further subdivided in α-, β-, γ-, and ω-gliadins and the glutenins 
into low molecular weight (LMW-) and high molecular weight (HMW-) glutenins. T cell 
stimulatory epitopes have been identified in all these proteins (7-13),(8;14;15).  
For patients with CD the only cure is a lifelong strict gluten-free diet (GFD), which 
in practice excludes all foods that contain wheat, barley, rye and oats. Because of the 
widespread use of gluten and gluten-like proteins in food products, a GFD has a great 
impact on the lifestyle of CD patients. For this reason the search for new treatments, 
which are compatible with a normal social lifestyle, is of great importance. In this re-
spect several lines of research have been proposed. Studies are performed in which 
wheat varieties are screened for the level of T cell stimulatory epitopes. Wheat varie-
ties with a low toxicity might form the basis for future breeding programs to generate 
wheat varieties suitable for generation of food products that can be consumed by CD 
patients (16-18). Another option is the use of enzymes that degrade the proline-rich 
gluten molecules before they reach the small intestine. In this context prolyl oligopep-
tidases were investigated. Such enzymes are not only effective in degrading gluten, the 
generation of smaller gluten fragments also improves the digestibility of gluten pro-
teins by rendering them more accessible to brush border enzymes (19-25). However, 
to avoid T cell recognition gluten must be degraded before it reaches the small intes-
tine and the prolyl oligopeptidases investigated are not active under the conditions 
found in the stomach. These enzymes are thus not suitable for oral supplementation as 
an alternative treatment for CD. 
Recently, we described a prolyl endoprotease from Aspergillus niger (AN-PEP) 
(39). This enzyme was found to efficiently degrade gluten peptides and intact gluten 
proteins. Moreover, the pH optimum of the enzyme is compatible with that found in 
the stomach and the enzyme is resistant to degradation by pepsin. These results indi-
cate that this enzyme might be suitable for oral supplementation to degrade gluten 
proteins in food before they reach the small intestine. To test this we determined the 
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efficiency of gluten degradation under near in vivo conditions. To predict the efficacy 
of enzymes and drugs for therapeutic use in the GI-tract of humans, a dynamic, multi-
compartimental in vitro system was developed (26). Validation studies demonstrated 
that this system, called TIM (TNO gastro-Intestinal Model), allows a close simulation of 
in vivo dynamic physiological processes that occur within the lumen of the stomach 
and small intestine of humans and reliably predicts in vivo data (27-29). The system is 
fully computerized and based on parameters obtained from data of healthy volun-
teers. The main parameters of digestion, such as pH, body temperature, peristaltic 
mixing and transit, salivary, gastric, biliary, and pancreatic secretions, as well as ab-
sorption of small molecules (e.g. nutrients and drugs) and water are simulated. GI 
passage and successive conditions can be adjusted in order to mimic parameters in 
humans at different stages (infant, adult, and elderly), different food intakes and phys-
iological or pathological conditions (such as gastric hyperacidity or pancreatic failure) 
(29;30). 
The result of the present study demonstrates that gluten degradation was strong-
ly accelerated by the presence of AN-PEP in the stomach compartment. AN-PEP was 
capable of degrading all T cell stimulatory epitopes of gluten tested for to levels below 
the detection limit of the methods used. Co-administration of AN-PEP with a gluten 
containing meal may thus be a feasible approach to detoxify gluten before it can do 
harm in the small intestine of CD patients. This may offer patients an alternative to the 
strict GFD and thereby improve their quality of life. 
 
 
MATERIALS AND METHODS  
 
Enzyme prolyl endoprotease from Aspergillus niger (AN-PEP) 
Prolyl endoprotease from Aspergillus niger (AN-PEP) was produced and purified by 
DSM Food Specialties (Delft, The Netherlands) according to established procedures 
(31). Activity of the protein is expressed in Proline Protease Units (PPU). A PPU is de-
fined as the quantity of enzyme that releases 1 µmol of p-nitroanilide per minute at 
37
0 
C in a citrate/disodium phosphate buffer pH 4.6 and at a substrate concentration of 
0.37 mM Z-Gly-Pro-pNA (Bachem, Bubendorf, Switserland) and represents 10 mg of 
pure protein. The reaction products were monitored spectrophotometrically at 405 
nM.  
 
TIM experiments  
The TIM has been described in detail previously (26-30). This model has compartments 
for the stomach, duodenum, jejunum and ileum (Figure 1). Each compartment has a 
flexible inner wall surrounded by water at 37º C. Changing water pressure squeezes 
the walls to simulate peristaltic mixing of the food with the ‘secreted’ electrolytes and 
enzymes. The transport of the chyme is regulated by the peristaltic valves that connect 
the successive compartments. Using various sensors in the compartments, the pH 
values, temperature, volumes, and pressure, as well as the gastric emptying and small 




the present experiments all parameters in TIM were adjusted to simulate the average 
physiological conditio
type of meal as described below. During 2.5 h the gastric content was gradually deli
ered into the small intestine via the ‘pyloric valve’. After 5 h approximately 80% of the 
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bottle) via the ‘ileo
 
Figure 1. 
small intestine (TIM system).
A. stomach compartment; B. pyloric sphincter; C. duodenum compartment; D. peristaltic valve; E. 
jejunum compartment; F. peristaltic valve; G. ileum compartment; H. ileo
electrodes; J. pancreatin, bicarbonate; L. secretion of bicarbo
pre
tem; P. closed dialysing system. 
For 2.5 hours the gastric content was mixed by peristaltic movements with added saliva and 
gas
KU/L (Sigma, P
Throughout the transit in the duodenum compartment the content w
movements with bicarbonate up to pH 6.4 ± 0.2 and with ‘secreted’ bile and pancreatic juice. 
Also in the jejunum and ileum compartments the content was mixed with bicarbonate up to pH 
6.8 ± 0.2 and pH 7.1 ± 0.2, respectively.  The d
from the jejunum and ileum compartments via semi
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Two experiments were performed. In the first experiment 70 g of white bread 
(containing 5 g of gluten) and 110 ml drinking water was homogenized together with 
110 ml of artificial saliva in the absence or presence of AN-PEP (200 mg pure enzyme/g 
protein). After 40 seconds of homogenization the mixture was added to the stomach 
compartment of the TIM-system containing 10 ml of simulated gastric juice and the 
experiment was started. In the second experiment a quarter of a commercial fast food 
menu consisting of a bread bun, a hamburger, ketchup, French fries, and supplement-
ed with additional bread (50 g in total), was homogenized with 110 ml soda and 110 ml 
of artificial saliva in the presence or absence of AN-PEP (200 mg pure enzyme/g pro-
tein) and introduced in the TIM-system. 
 
Sampling and analysis 
During the transit of the homogenized food products through the compartments of the 
TIM-system, samples of 2 ml were taken at time points: 0, 15, 30, 45, 60, 90, 120, 150, 
180 and 240 minutes from the stomach, duodenum, jejunum and ileum compart-
ments. The samples were snap frozen in dry ice to stop enzymatic activity. 
Before analysis, the samples were thawed and AN-PEP activity was stopped by in-
creasing the pH to 11-12 using 1 M NaOH, followed by neutralization with 1M HCl. 
Hereafter the samples were kept at 85° C for 10 minutes to inactivate any residual 
enzymatic activity. Identical volumes from each sample were centrifuged for 10 
minutes at 14.000 rpm to separate the water-soluble and water-insoluble components. 
The water-insoluble fractions were solubelized in the same volume of 6x protein sam-
ple buffer (60% glycerol, 300 mM Tris (pH 6.8), 12 mM EDTA pH 8.0, 12 % SDS, 864 mM 
2-mercaptoethanol, 0.05% bromophenol blue). From these solutions 2 μl from each 
sample was used for the protein and Western blot analysis.  
 
Synthetic peptides 
Peptides were synthesized as described previously (32). 
 
MAb against the Glia-α20, Glia-α9, Glia-γ1, LMW and HMW glutenin T cell 
stimulatory epitopes 
The specificity and the IgG subclass of the antibodies used in this study are presented 
in Table 1. 
For the generation of a mAb specific for the α-gliadin derived T cell stimulatory 
epitope Glia-α20, mice were immunized with peptides chemically cross-linked to teta-
nus toxoid (TTd-DDDXPFRPQQPYPQP-amide). Fusion and screening of the hybridomas 
was performed as described (32). The minimal epitope of the anti-Glia-α20 mAb 






Table 1. Overview of mAbs specific for T cell stimulatory epitopes involved in celiac disease. 
Specificity T- cell epitope mAb specificity mAb subclass 
α-Gliadin Glia -a9 QLQPFPQPQLPY IgG1 (k light chain) 
  Glia-a20 QPQPFRPQQPYPQPQP IgG1 (k light chain) 
γ-Gliadin Glia-γ1 QPQQPQQSFPQQQRPFI IgG1 (k light chain) 
LMW- glutenin Glt-156 QPPFSQQQQSPFSQ* IgG3 (k light chain) 
    QPPFSQQQQSPFSQ** IgG1 (k light chain) 
HMW-glutenin   QQGYYPTSPQQSG IgG1 (k light chain) 
* antibody used for staining western blots 
** antibody used in competition assays experiments 
 
 
Competition assays for the quantitative detection of T cell stimulatory 
epitopes 
Competition assays were performed as described earlier (16;32). Microtitre plates 
(Nunc Maxisorb, Immunoplate; Nunc, Copenhagen, Denmark) were incubated over-
night with 2–5 µg/ml mAb in 0.1 M sodium carbonate/bicarbonate buffer, pH 9.2, at 
room temperature. Plates were washed in PBS/0.02% Tween-20 and residual binding 
sites were blocked with PBS/ 1% skim milk powder (Fluka, Zwijndrecht, the Nether-
lands). Of the gluten containing samples, different dilutions were made in a buffer 
containing 50 mM Na2HPO4/NaH2PO4 pH 7.0, 150 mM NaCl, 0.1% Tween-20/ 0.1% skim 
milk and a protease inhibitor cocktail (Complete, Roche Diagnostics GmbH, Penzberg, 
Germany). For the detection of gliadins these were mixed with either a biotinylated 
Glia-α9 or Glia-γ1 gliadin T cell epitope encoding peptides (32). For the detection of 
the Glia-α20 T cell stimulatory epitope a biotinylated peptide encoding the Glia-α20 
epitope was used as the indicator peptide (Bio-XKAKAKAKAXPFRPQQPYPQP-amide). 
For quantification, a standard curve was made using the Prolamine working group 
(PWG) gliadin reference material (33) in the concentration range 10 μg/ml-10 ng/ml 
mixed with biotinylated indicator peptides. The assays, specific for the detection of T 
cell stimulatory epitopes of LMW glutenin, were calibrated using a 25-mer synthetic 
peptide as standard that contains the Glt-156 epitope (16). The HMW-glutenin specific 
assay was calibrated using a chymotrypsin digest of six purified HMW-glutenin proteins 
(kindly provided by P. Shewry, Rothamsted Research, Hampenden, United Kingdom) 
Both standards were used in a concentration range from 1 µg/ml-2 ng/ml. 
The mixtures were incubated on plates for 1.5 hours at room temperature. Next, 
plates were washed and incubated for 30 minutes with streptavidin conjugated horse-
radish peroxidase in PBS/ 0.1% skim milk. 
Thereafter, bound peroxidase was visualised by incubation with a solution of 3’, 
3’, 5, 5’-tetramethylbenzidine (Sigma-Aldrich Zwijndrecht, the Netherlands). Finally, 
absorbance at 450 nm was read on a Multiscan plate reader (Wallac, Turku, Finland). 
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Protein analysis by 1D SDS-PAGE and Western blotting 
To determine the level of T cell stimulatory epitopes present in the water-insoluble 
fractions, these were solubilized in 6x protein sample buffer (60% glycerol, 300 mM 
Tris (pH 6.8), 12 mM EDTA pH 8.0, 12 % SDS, 864 mM 2-mercaptoethanol, 0.05% bro-
mophenol blue). The samples were separated on a 12.5% SDS-PAGE gels for detection 
of gliadins and LMW glutenins and on 10% SDS-PAGE gels for detection of HMW 
glutenins. The proteins were visualized either directly using Imperial Protein Stain 
(Pierce, Rockford IL, USA), or after transfer to PVDF membranes with the mAbs specific 
for stimulatory T-cell epitopes from α- and γ-gliadin (32)(and this study) and HMW- 
and LMW glutenins (16). 
 
T-cell proliferation assay 
For the T cell proliferation assays the samples were treated with amylglucosidase and 
trypsin. Next the samples were incubated O/N at 37°C with guinea pig tissue transglu-
taminase (200 ug/ml) in the presence of  10 mM CaCl2. Proliferation assays were per-
formed in triplicate in 150 μl Iscove’s Dulbecco’s medium (BioWhittaker, Vervier Bel-
gium) supplemented with 10% human serum in 96-well flat bottom plates (Costar, 
Corning Inc., Corning, USA) using 10
4  
gluten specific T-cells stimulated with 10
5 
irradi-
ated HLA-DQ2-matched allogenic PBMCs (3000 RAD). Of the samples three different 
amounts of the samples were tested: 0.5 ul, 0.16 ul and 0.05 ul respectively. These 
amounts were shown to be none toxic for the T-cells. After 48 h incubation at the 
37°C, cultures were pulsed with 0.5 μCi of 
3
H-thymidine, harvested 18h later and the 
thymidine incorporation was quantified with a liquid scintillation counter (1205 Be-





Digestion of bread and a fast food menu in the TIM-system 
To study the effect of AN-PEP on the degradation of gluten proteins in the GI-tract, two 
experiments were performed. These experiments were designed to represent a small 
meal (e.g. breakfast) and a more complex meal (e.g. dinner). In the first experiment 70 
g of white bread was homogenized together with artificial saliva in the presence or 
absence of AN-PEP. In the second experiment a quarter of a fast food menu consisting 
of a sandwich, a hamburger, ketchup, French fries and a glass of soda was homoge-
nized with artificial saliva in the presence or absence of AN-PEP. Since the quantity of 
bread in this menu was relatively low (16 g), extra bread was added to a total amount 
of 50 g. After homogenization the mixtures were introduced in the TIM-system, mim-
icking the human GI-tract (Figure 1). Samples were collected at time points 0, 15, 30, 
45, 60, 90, 120, 150, 180 and 240 minutes after the start of the experiment from the 
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In order to study the degradation of gluten in the TIM-experiments, three types of 
assays were performed. The presence of gluten peptides in the water-soluble fractions 
was measured by monoclonal antibody (mAb) based competition assays specific for T 
cell stimulatory peptides present in gliadin (Glia-α9, Glia-α20, Glia-γ1) and LMW- and 
HMW-glutenin (16;32) (this study). The presence of T cell stimulatory epitopes from 
gluten in the water-insoluble fractions was determined by Western blot analysis. 
Moreover samples of the fast food menu taken at 60 minutes after the onset of the 
experiment were tested by T cell proliferation assays. 
 
AN-PEP accelerates the degradation of gluten present in white bread 
After the introduction of the white bread to the TIM-system, the levels of all gluten 
peptides tested steadily decreased in the water-soluble compartment in the absence 
of AN-PEP. However, even after 120 minutes significant levels of gluten peptides were 
still detectable in the stomach compartment (Figure 2). In contrast, when the white 
bread was introduced together with AN-PEP the digestion of gliadins (Figure 2A and 
2B) and glutenins (Figure 2C and 2D) was accelerated at all time points.  
Samples that were collected from the duodenum, jejunum and ileum compart-
ments contained very low levels of gluten peptides. In the case of digestion in the 
presence of AN-PEP no gluten peptides could be detected in these samples at all (re-
sults not shown). 
Similarly, the Western blot analysis indicated that the degradation of gluten due 
to the addition of AN-PEP was accelerated. In the water-insoluble fractions of the 
stomach compartment α-gliadin, γ-gliadin and HMW-glutenin proteins were detecta-
ble (Figure 3). Although a significant degradation of gluten was seen in the absence of 
AN-PEP, both gliadins (Figure 3A and 3B) and glutenins (Figure 3C) were still present 
after 120 minutes in the stomach compartment. In the presence of AN-PEP, however, 
faster degradation of both the gliadins (Figure 3A and 3B) and the glutenins (Figure 3C) 
occurred. This difference in degradation is already apparent after 45 minutes, and 
after 90 minutes gluten proteins could no longer be detected in the AN-PEP treated 
fractions (Figure 3).  
The duodenum fractions contained only a small amount of water-insoluble mate-
rial. Western blot analysis failed to detect intact gluten proteins in these fractions, 
neither in the absence nor presence of AN-PEP (results not shown).  
 
AN-PEP accelerates the degradation of gluten present in a complex meal 
In the second experiment the digestion of gluten in a fast food menu was monitored. 
In the absence of AN-PEP, gluten peptides were found to be degraded in the water-
soluble fraction. However, residual gluten peptides were still detectable in the frac-
tions collected from all compartments up to 150 minutes after the start of the experi-
ment (Figure 4). In the presence of AN-PEP, the degradation of gliadins (Figure 4B) and 
glutenins (Figure 4D) was accelerated. In the absence of AN-PEP, gluten peptides could 
be detected in the samples that were collected from the duodenum, jejunum and 
ileum compartments (Figure 4A and 4C). In the presence of AN-PEP much lower 
amounts of gluten peptides could be detected in these samples (Figure 4B and 4D). 
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Again, the analysis of the water-insoluble material collected from the stomach 
and duodenum compartment indicated accelerated degradation of the gluten in the 
meal. In the presence of AN-PEP the amount of α-gliadin is clearly decreased in the 
stomach compared to the digestion in the absence of AN-PEP (Figure 5A). Directly after 
homogenization (t = 0 min) a clear difference is apparent and after 60 minutes no 
more gluten proteins could be detected in the AN-PEP samples while such proteins 
were clearly still present in the control samples. Similarly, the HMW-glutenins were 
degraded faster in the presence of AN-PEP (Figure 5C). After 60 minutes no more 
HMW-glutenins could be detected in the AN-PEP fractions while partially degraded 
HMW-glutenins were still present in the control fractions (Figure 5C). Finally, the deg-
radation of the γ-gliadins and LMW-glutenins was similarly enhanced by the addition of 
AN-PEP (Figure 5B and 5D).  
Similar to the white bread experiment, the amount of water-insoluble material in 
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It is well established that CD patients are intolerant to gluten and that a strict gluten-
free diet (GFD) is an effective treatment for CD. The lifelong maintenance of such a 
diet, however, is hard to achieve. First of all, the diet in the western world is heavily 
based on gluten containing foods like bread and pasta. In addition, because of its spe-
cial properties, like its elasticity and capacity to bind water, gluten is often added to 
foods that would otherwise be gluten-free. Finally, many foods that are rendered glu-
ten-free may still contain traces of gluten while naturally gluten-free ingredients are 
often contaminated with gluten. CD patients, therefore, can inadvertently be exposed 
to gluten. Moreover, a GFD can cause social constraints and this can lead to non-
compliance with the diet. For these reasons an alternative to a GFD would be useful to 
patients. Oral supplementation with enzymes to degrade gluten before it causes dam-
age has been suggested for this purpose. Initially this proposition was based on the 
theory that CD is caused by an enzyme deficiency (34) and the use of non-human pro-
teases for gluten detoxification was already proposed in the late fifties (35). Recently a 
clinical trial was performed in which an extract from animal intestines was used. It was 
shown that the enzyme therapy offered better protection than placebo. However, the 
differences between enzyme therapy and placebo were small and no complete protec-
tion was given by the extract. Furthermore, not all patients did benefit to the same 
extent from the enzyme supplementation (36).  
As gluten is rich in the amino acid proline, other recent studies have used post-
proline cutting enzymes. Promising enzymes tested are the prolyl oligopeptidases from 
Flavobacterium meningosepticum, Sphingomonas capsulate, and Myxococcus xanthus. 
These enzymes are capable of degrading proline containing peptides that are other-
wise resistant to degradation by proteases in the gastrointestinal tract in vitro 
(23;37;38). However, the suitability of these enzymes to degrade gluten in vivo is ques-
tionable since the enzymes have a pH optimum between 7 and 8 and do not function 
at the acid pH of the stomach. Moreover, they are efficiently broken down by pepsin 
(23). Finally, due to their structure, in which a β-propeller domain restricts entry into 
the active site of the enzymes, they preferentially cleave short peptides (39). Encapsu-
lation of these prolyl oligopeptidases was proposed to protect them against gastric 
juice (38). However, in a recent ex vivo study, using biopsy-derived intestinal tissue 
mounted in Ussing chambers, it was observed that only high dosages of prolyl oligo-
peptidase tested were capable to eliminate the accumulation of immunogenic pep-
tides in the serosal compartment (21). This indicates that, even if the enzyme is encap-
sulated, due to the relatively low efficiency the prolyl oligopeptidase will not be able to 
degrade gluten before it reaches the proximal part of the duodenum, the site where 
gluten triggers inflammatory T cell responses. To overcome these problems a combina-
tion therapy has been proposed. For this the prolyl oligopeptidase is combined with a 
cysteine endoprotease from barley whose natural function is to degrade the gluten-
like molecules in barley, to the benefit of the germinating seed. While such a combina-
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tion therapy may prove effective, a therapy based on one enzyme would have obvious 
advantages (40).  
Recently, we have investigated a prolyl endoprotease of Aspergillus niger, AN-PEP 
(31). We observed that AN-PEP has clear advantages over prolyl oligopeptidases as it is 
much more efficient in degrading gluten peptides, is active at low pH, and resistant to 
pepsin degradation (31;41). Moreover, as AN-PEP is a prolyl endoprotease, it degrades 
gluten peptides as well as intact gluten proteins (31;41).  
These results indicated that AN-PEP may be suitable as an oral supplement for 
gluten degradation but its efficacy in vivo remained to be established. Although this 
can be tested in animal models, as has been carried out for a prolyl oligopeptidase, the 
relevance of this for the human situation is debatable as the gastrointestinal tract of 
animals only partly reflects that of humans. We have therefore chosen to study the 
efficacy of AN-PEP using a dynamic gastrointestinal model that closely mimics the in 
vivo conditions found in the human stomach and small intestine (26-28). Moreover, we 
have tested the capacity of AN-PEP to degrade gluten when present in a relatively 
simple food matrix, e.g. white bread, as well as when gluten is present in complex food 
matrix, e.g. a complete fast food meal. The results of this study show that AN-PEP is 
indeed capable of degrading gluten under conditions found in the human GI-tract. We 
have carried out three types of analysis: competition assays that measure the presence 
of small gluten fragments in the water-soluble fractions, Western blot to measure 
intact gluten proteins and relatively large fragment thereof (> 5 kD) and T cell prolifer-
ation experiments that measure the presence of gluten derived T cell stimulatory pep-
tides. Both the competition assays and the Western blot analysis gave comparable 
results: the disappearance of gluten proteins as indicated by Western blot analysis also 
led to a disappearance of smaller gluten peptides as measured in the competition 
assay. Moreover T cell proliferation assays on samples collected at 60 minutes from 
the digesting fast food menu showed that after the addition of the AN-PEP, the stom-
ach content is no longer capable to induce a T cell proliferation. Taken together, these 
results indicate that AN-PEP completely degrades gluten into harmless fragments with-
in 2 hours, the average passage time of food in the stomach. Besides, during the stay 
of the gluten in the stomach, the level of T cell stimulatory epitopes of α- and γ-gliadin 
HMW-glutenin and LMW-glutenin epitopes in the water soluble fragments were signif-
icantly lower in the presence of AN-PEP than in the absence. This results in much lower 
amounts of T cell stimulatory epitopes that are released from the stomach into the 
duodenum, thereby reducing the exposure of the proximal duodenum with T cell acti-
vating peptides. Moreover, in a previous study we have already demonstrated that AN-
PEP will efficiently cut the alpha-gliadin peptide 31-43 and thus destroy the innate 
stimulatory properties of gluten. 
It is important to note that our results may underestimate the rate of gluten deg-
radation in the human body. Although the TIM-system simulates the lumen of the 
human GI-tract, including peristaltic movements, secretion of juices from the salivary 
gland, the stomach, pancreas and liver, no brush border enzymes are present in the 
model. As brush border enzymes have an additive effect on proteolysis, which is also 
shown for the breakdown of gluten proteins (25), it is likely that the degradation of 
gluten is even more efficient than indicated by our results.  
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In conclusion, we have tested the effect of the addition of AN-PEP on gluten deg-
radation in a system that closely mimics the conditions in the upper human GI-tract. 
Our results demonstrate that within the time span that food is normally present in the 
stomach, co-administration of AN-PEP led to a complete disappearance of T cell stimu-
latory peptides of gliadins and glutenins. Importantly, our results demonstrate that 
AN-PEP is capable of degrading gluten when this is present in a complex food matrix. 
Moreover, AN-PEP is derived from the food grade microorganism Aspergillus niger and 
available on industrial scale. Ultimately, clinical trials will be required to determine if 
oral enzyme supplementation can remove all gluten toxicity. Our results indicate that 
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Currently the only treatment for celiac disease is a lifelong gluten-free diet. While very 
effective it is cumbersome as wheat based products are so commonly used in our daily 
diet. Many food products are therefore off limits for celiac disease patients. Moreover, 
gluten is often present as a hidden ingredient which can lead to inadvertent exposure 
to gluten. While many patients are content with their gluten-free diet, others would 
welcome alternative treatments and/or food products that would allow more flexibil-
ity. The research presented in the present thesis focuses on the development of such 
alternatives. 
Celiac disease is an HLA-associated disease: it develops almost without exception 
in HLA-DQ2 and/or HLA-DQ8 individuals (1-3). There are many other HLA-associated 
diseases, like type I diabetes and rheumatoid arthritis, but only in celiac disease the 
disease-causing agent is known: wheat-derived gluten and similar proteins in other 
cereals. Around 1950 Willem Karel Dicke first observed the connection between cereal 
intake and the presence of symptoms in children with celiac disease (4). He found that 
during the Second World War, when wheat products were scarce, his patients got 
better but relapsed when wheat was reintroduced after the war. Later research 
demonstrated that the symptoms were caused by the gluten and gluten-like storage 
proteins in wheat and related cereals (5). Based on these observations the gluten-free 
diet was introduced: when a patient does not consume wheat, barley and rye products 
she/he does not experience any symptoms. The definition of a treatment is that it 
treats a problem and may lead to its cure but more often the treatment ameliorates a 
problem only for as long as it is applied. This is also the case in celiac disease, the glu-
ten-free diet offers release of symptoms only as long as it is followed and therefore 
must be maintained lifelong.  It’s main disadvantage is that it can restrict participation 
in social events, traveling and eating out which causes more problems to the newly 
diagnosed and to young patients.  
In the present thesis three alternative approaches to the gluten-free diet are pre-
sented and discussed. These approaches are: the development of cereals or gluten 
with no or low immunogenic content, the use of oats as an alternative cereal, and the 
use of enzymes for gluten detoxification.  
 
Better detection methods 
In order to determine gluten toxicity, appropriate reagents need to be available to 
detect such toxicity. Earlier studies had defined the epitopes responsible for the im-
mune response. These were found to be peptides derived from both gliadins and 
glutenins (6-9). All such peptides have been identified with the use of patient derived T 
cells specific for such peptides when bound to the disease predisposing HLA-DQ2 or 
HLA-DQ8 molecules. Therefore, the golden standard for testing the immunogenicity of 
food products would be the use of such gluten specific T cells isolated from the small 
intestine of celiac patients. Unfortunately, they can not be used for routine screening 
purposes as they are highly sensitive for various compounds commonly found in food, 
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can only be employed in a sterile environment and testing is time consuming and ex-
pensive. For this reason antibody-based systems are commonly employed. The vali-
dated gluten detection method currently employed is based on the R5 monoclonal 
antibody that was raised against a barley epitope and also reacts with sequences from 
gliadins and rye (10,11). Unfortunately, the epitope recognized by the R5 antibody 
does not represent the known toxic sequences of gluten and therefore does not meas-
ure gluten toxicity. Ideally, antibody-based gluten detection systems would employ 
antibodies that are raised against known T cell stimulatory sequences in gluten and 
have a reactivity pattern that closely resembles that of gluten specific T cells. 
For this purpose five monoclonal antibodies were raised in our laboratory that de-
tect known gluten epitopes namely: Glia-alpha-20, Glia-alpha-9, Glia-gamma-1, the 
LMW-glutenin 156 and the HMW glutenin epitope (12-14). These antibodies were used 
to set up a competition based assay that can detect the presence of these epitopes 
both in peptides mixtures and proteins. All 5 antibodies were shown to be suitable for 
gluten detection in Western blot analysis as well. The fine specificity of these antibod-
ies for gluten and gluten-like peptides and proteins was determined and compared 
with that of the gluten specific T cells (Chapter 2). It was shown that, just like the glu-
ten specific T cells the antibodies react with homologous peptides found in epitopes 
from barley, rye and triticale and that the specificity partially overlaps with that of the 
corresponding T cells (15). Such antibody reagents are therefore very suitable for the 
detection of gluten, in particular sequences that are linked to gluten toxicity for celiac 
disease patients. Therefore these antibodies were used in the subsequent studies 
aimed at the development of alternatives for the gluten-free diet.  
Moreover, in collaboration with the diagnostics company Europroxima, one of the 
antibodies has been used to generate a gluten detection kit that has been tested in an 
international RING-trial in 2009/2010 in which 10 laboratories participated. As the 
results of this trial were positive and the new kit has several advantages over the 
commercially available R5 test kit, it was launched on the market in June 2010 and may 
ultimately replace the R5 based method.  
 
Towards low toxic wheat and safe gluten proteins 
As wheat is so important for food production in industrialized countries, one would like 
to have a wheat variety available that would be suitable for consumption by celiac 
disease patients. With the identification of the immune stimulatory sequences in the 
gliadins and glutenins it became possible to investigate if differences exist between 
wheat varieties or gluten proteins with regard to toxicity for celiac disease patients. 
Indeed, it could be shown that natural variation exists in the immunogenic content of 
wheat varieties, especially between varieties belonging to different genotypes (14,16). 
This sparked the hope that a non-toxic hexaploid bread wheat variety could be identi-
fied. The benefits of a non-toxic hexaploid wheat are obvious as they have good crop 
yield and good baking quality and could thus be easily used in the food industry. Ideal-
ly, this would form the basis for the production of food products that would have the 
same nutritional value and the smell, texture and taste typical for normal wheat based 
products. Further research, however, indicated that it is highly unlikely that natural 
wheat varieties exist that are safe for consumption by patients. The analysis of over 
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3000 gliadin genes indicated that none encoded a protein that would be entirely de-
void of toxicity. Moreover, all ancient wheat varieties that we tested proved to contain 
immunogenic epitopes, although to a lesser extent than the hexaploids bread wheat 
varieties. 
The results, however, offered an alternative approach to eliminate gluten toxicity 
(Chapter 3). Extensive testing of all existing variants of known immunogenic peptides 
in gluten proteins indicated that some of these variants lacked immunogenic proper-
ties. For example, a variant peptide present in the A genome contains one single amino 
acid substitution that rendered the epitope non-immunogenic. This single amino acid 
substitution concerned the replacement of the proline at relative position 8 in the 
peptide by a serine. Interestingly the majority of HLA-DQ2-restricted gluten epitopes 
contain a proline at this position (17) moreover, we observed that the introduction of 
this proline to serine substitution eliminated the immunogenic properties of all these 
peptides, including the highly immunogenic 33-mer found in the alpha-gliadin proteins. 
We used this knowledge to device a general strategy to eliminate gluten toxicity in 
alpha-gliadin proteins and provided proof of principle at the peptide level. Similar 
approaches are likely to be applicable to other gluten proteins as well. These results 
can now be applied and may lead to large scale production of safe gluten proteins for 
incorporation in “gluten-free” foods meant for celiac disease patients. 
Thus, in our search for a non-toxic cereal we failed but we did find a way to detox-
ify gluten. 
 
Alternative cereals: oat 
While it is well established that wheat, barley and rye can not be tolerated by celiac 
disease patients, oat is considered a reasonable safe alternative. In the last 10 years, 
however, the introduction of oat in the gluten-free diet was surrounded by controver-
sy since not all patients tolerate oat (18). “Oat toxicity” was partially explained by the 
discovery that the large majority of oat samples were contaminated with wheat, barley 
or rye during cultivation, transport and/or processing (19). To overcome this problem 
contamination-free oat chains have been set up in Scandanavia and more recently also 
in The Netherlands. Another problem surrounding oat is that it was found that gluten 
reactive T cells can cross react with peptides derived from the gluten-like avenin pro-
teins in oat and the isolation of avenin specific T cell clones from a celiac disease pa-
tient that was intolerant to oat (7,20). Thus, oat does contain some peptides that can 
elicit immune responses but the level of exposure is apparently so low that most pa-
tients can consume oat without problems. To determine if all oat varieties are equally 
immunogenic we tested a representative collection of oat samples used in the Nether-
lands (Chapter 4). We observed that all oat samples tested contain immunogenic 
epitopes but that their presence is variable. Thus, just like in wheat, also in oat there is 
a natural variation in the immunogenic content. We also identified a monoclonal anti-
body which specifically detects avenin epitopes, the use of which will make the testing 
for intrinsic toxicity easier. The results indicate that though testing of the immunogen-
icity of oat, low or non-toxic varieties may be identified that will allow oat consump-




The use of enzyme therapy for gluten detoxification 
Oral supplementation with enzymes in order to diminish the exposure of patients to 
hidden gluten was proposed already in the late 1950 when was thought that celiac 
disease was due to a lack of enzymes (21,22). The first enzyme of choice was papain, 
but the results of the experiments were poor (22). The following attempt was per-
formed with an extract from animal intestine (23). This clinical trial did show a certain 
protection in comparison to the placebo, but not all patients benefited to the same 
extent. Since the high proline content of gluten is one of the reasons for its poor deg-
radation in the gastro-intestinal tract the use of post-proline cutting enzymes was 
proposed (24-26). Promising enzymes that were tested are the prolyl oligopeptidases 
from Flavobacterium meningosepticum, Sphingomonas capsulate and Myxococcus 
xantus, which were shown to cut proline rich gluten proteins (25-28). These enzymes, 
however, have a drawback since they can not function in the acid milieu in the stom-
ach and can also be degraded by pepsin. They are thus not able to degrade gluten 
before it reaches the upper part of the small bowel where the characteristic celiac 
disease lesions are found. 
An alternative enzyme is the prolyl endoprotease of Aspergillus niger, AN-PEP. It 
was already shown that this enzyme has several advantages over the previously de-
scribed enzymes since it is more efficient in degrading gluten peptides, is active at a 
low pH and is resistant to pepsin degradation (29). During my research we took the 
testing of this enzyme to the next level and we showed that AN-PEP is capable to de-
grade gluten present in a simple bread meal and also in a more complex bread contain-
ing meal in a system that mimics the human gastro-intestinal tract (Chapter 5). The 
samples recovered from the “digested” meal were found to no longer contain immu-
nogenic sequences when tested with specific monoclonal antibodies and more signifi-
cantly with gluten specific T cells. These promising results form the pre clinical phase of 
a clinical trial which has already shown that the enzyme can be safely consumed by 
patients (Table 1). A larger clinical trial will have to demonstrate that the enzyme is 
useful for gluten degradation in humans and can prevent the reappearance of symp-
toms when patients consume gluten. 
 
Table 1. Description of AN-PEP clinical trial 
Phase Description Results 
pre clinical In vitro experiments 
Effective degradation of known 




no side effects by oral  
administration 
II determination of optimal dose not performed 
III 
comparison to known therapies, 
testing combination therapies and 
different doses 
not performed 




The future: from bench to the patient 
The best reward for any research is to see it applied. The focus of my research has 
been on the development of alternatives to the current gluten-free diet. Parts of the 
results presented in this thesis are closer to application than others. The detection of 
immunogenic gluten and gluten-like epitopes with the use of monoclonal antibodies is 
closest to being exploited and the anti-Glia-alpha-20 antibody is already incorporated 
in a detection kit which has been successfully tested in a ring trial. Since this kit detects 
a non-repetitive immunogenic gluten epitope and uses a synthetic peptide as a stand-
ard, it offers a better gluten quantification method compared to the existing method 
based on the R5 antibody. The kit was launched on the market in June 2010. While this 
kit is primarily meant for industrial use, it may be possible to design a variant that 
would allow patients to test food products themselves.  
Also, the results on oat toxicity can be readily applied to ensure safety of oat con-
sumption by patients. Unfortunately, the situation is much more complex when it 
comes to wheat. Large scale screening of gliadin genes indicated that non-toxic gliadin 
proteins do not exist. Accordingly, all tested hexaploid, tetraploid and diploid wheat 
varieties were found to contain toxic epitopes. It is thus highly unlikely that true non-
toxic wheat can be obtained through conventional breeding programs. However, dur-
ing these screening programs we discovered naturally occurring amino acid mutations 
in gliadin epitopes which eliminate the T cell stimulatory properties of these epitopes. 
This now allows the design and expression of modified gliadin genes for the production 
of non-toxic gluten. As the introduced amino acid modifications are naturally occurring 
it is expected that the modified proteins will have retained much of the desired tech-
nological properties and nutritional value of the original gluten proteins. Likewise, a 
similar detoxification method could be used to eliminate the toxicity of the gamma–
gliadins, LMW- and HMW-glutenins, allowing the production of complex but non-toxic 
mixtures of gluten proteins. Although this approach is straightforward, the realization 
of “Safe Gluten” is still not around the corner. The genetic code of gluten genes will 
have to be changed and expressed in recombinant fashion, creating genetically modi-
fied crops producing recombinant gluten proteins. Apart from public acceptance and 
regulatory issues, it is unknown how efficient the production would be and it remains 
to be demonstrated that such “Safe Gluten” is indeed safe for consumption by pa-
tients. It will be several years before this point is reached.  
Gluten with low dose epitope content can be obtained on a much shorter term ei-
ther through selection of varieties with low epitope content of by specific amino acid 
mutations at key positions in known epitopes. By replacing gluten with this “lower 
epitope dose” gluten the risk of development of celiac disease may be lowered result-
ing is a reduced incidence of the disease. 
The introduction of enzymes for gluten detoxification may be much closer at 
hand. After demonstrating that AN-PEP can degrade gluten in an artificial gastrointes-
tinal system, the enzyme was tested in a small group of patients which showed that its 
consumption is not associated with adverse symptoms. Next it will have to be tested if 
AN-PEP can offer patients good protection against immunogenic wheat present in the 
diet. For this a large scale clinical trial needs to be executed. At present it is not clear if 
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the enzyme can offer protection against all wheat containing products since it needs to 
have access to the gluten in the food matrix and it is likely that this differs between 
food products. Therefore, it is unpredictable if AN-PEP will ever be able to replace the 
gluten-free diet. However, considering that AN-PEP has excellent gluten degrading 
capacity in vitro, it is likely that AN-PEP can be applied to safeguard celiac disease pa-
tients against unwanted gluten intake, for example during traveling or eating out.  
 
Future prospects 
While Dicke recognized already around 1950 that wheat and related cereals were 
causing celiac disease, it was not until the end of the last century that the molecular 
basis for this was unraveled. Now we know that gluten contains a multitude of immu-
nogenic peptides that can be modified by tissue transglutaminase and bind to the 
disease predisposing HLA-DQ2 or -DQ8 molecules and trigger inflammatory T cell re-
sponses. Although much is still unknown – i.e. why do not all HLA-predisposed individ-
uals develop disease and what triggers inflammatory responses in the epithelium? – 
we can try to exploit the current knowledge to the benefit of patients. This was the 
goal of the work described in the present thesis. In particular it was investigated if it 
would be possible to develop wheat or gluten proteins that would be safe for con-
sumption by patients and if it is possible to enhance gluten degradation with a post-
proline cutting enzyme isolated from Aspergillus niger. With the development of safe 
wheat patients would be able to consume a “normal” diet. Moreover, such wheat 
could be used to prevent the development of celiac disease in children born in high 
risk families. On the other hand, co-administration of a gluten degrading enzyme with 
a gluten-containing meal might allow patients to consume such meals. These two ap-
proaches are thus seemingly each others enemy: safe wheat would eliminate the need 
for enzymatic degradation while an effective enzyme therapy would eliminate the 
need for safe wheat. In reality the truth lies in the middle. There is no safe wheat and 
the development of safe gluten is still several years away from actual realization. It is 
also largely unknown how cost effective such safe gluten proteins can be produced 
and incorporated in foods for patients. On the other side it is unclear if enzymatic deg-
radation of gluten in the gastrointestinal tract will be so effective that it will allow the 
introduction of a normal gluten containing diet. Thus, both options are still open and 
deserve to be explored further.  
Next to better treatment options for patients, prevention of celiac disease devel-
opment is an ultimate goal of research in this area. Given the importance of cereal-
based products for nutrition worldwide exposure to gluten is unlikely to change signifi-
cantly in the future. Reduction of the incidence of celiac disease can thus only be 
achieved by targeted intervention in high risk families. Delayed introduction of gluten 
and deliberate exposure to low amounts of gluten early in life are two approaches that 
are currently being tested. Ultimately, better markers for prediction of the risk of dis-
ease development will be required for the design and implementation of more specific 
intervention protocols. While genetic studies are rapidly identifying such markers, 
these studies also demonstrate that many gene variants are implicated, each with a 
low impact. The unraveling of this complex genetic picture will take many years, years 
in which a gluten-free diet will likely remain the safest option for celiac disease pa-
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tients. Nevertheless, it is reasonable to assume that the work described in this thesis 
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What is known about celiac disease? 
Celiac disease is one of the most common food intolerances, approximately 1% of the 
population being a celiac disease patient. It is now known that celiac disease is precipi-
tated by ingestion of gluten, the major storage proteins in wheat, and similar proteins 
in related cereals like barley, rye and triticale (hybrid between wheat and rye). The 
most common complains of patients consuming gluten are abdominal pain, diarrhea 
and vomiting. Also neurological symptoms, infertility and retardation of growth can 
occur.  For a positive diagnosis of celiac disease a histological examination of a small 
bowel biopsy and a clinical improvement upon the introduction of a gluten-free diet is 
required. None invasive, serological assays are available that measure the presence 
and titer of IgA antibodies specific for gliadin, deamidated gliadin, endomysium and 
tissue transglutaminase. Almost without exception celiac disease develops only in 
genetically predisposed individuals: over 98% of the patients express either HLA-DQ2 
or HLA-DQ8. Next to the genetic component also other factors especially environmen-
tal play a role in disease development. 
Celiac disease is an immune mediated disease, in which gluten peptides come in 
contact at the level of the small intestine with gluten specific T cells. These T cells 
could only be isolated from the small intestine of patients and not of healthy controls. 
Specific gluten sequences rich in prolamine and glutamine amino acids, resist degrada-
tion in the gastro-intestinal tract and after deamidation by the enzyme tTg are recog-
nized by T cells. As a result of the inflammation, the mucosa loses its villi and strongly 
diminishes the absorption surface causing specific symptoms associated with the dis-
ease.  
The current treatment for celiac disease is strict adherence to a life-long gluten-
free diet. The wide-spread use of gluten and gluten-derived starch in the food industry 
makes the gluten-free diet challenging. It is not surprising that a considerable propor-
tion of patients, especially adolescents, are interested in alternative treatments that 
would allow gluten consumption.   
 
Thesis content 
My project, which makes the content of this book, has focused on the development of 
alternatives to the gluten-free diet. Two different approaches were investigated: the 
use of enzymatic supplementation and the identification and/or development of a 
less/non-toxic cereal.  
Chapter 1 is a general introduction to celiac disease. 
In chapter 2 the characterization of monoclonal antibodies raised against T cell 
stimulatory gluten peptides is described. Their reactivity against the prolamins from 
wheat, barley, rye and oats was determined and compared with that of gluten reactive 
T cells. The results demonstrate that the antibody and T cell reactivity patterns overlap 
significantly, indicating that the antibodies can be used to detect toxic sequences in 
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gluten. Subsequently, these antibodies were used in the studies aimed at the devel-
opment of alternative to the gluten-free diet.  
In chapter 3 we propose a new strategy to generate non-toxic gluten. Our exper-
iments demonstrated that non-immunogenic epitope variants were present in certain 
diploid wheat varieties that differ one amino acid with the toxic variant.  Moreover, we 
found that by the introduction of this naturally occurring amino acid substitution in 
other toxic epitopes their T cell stimulatory activity was likewise eliminated. This ap-
proach can thus be used to generate gluten genes that are devoid of any T cell stimula-
tory activity and presumably safe for consumption by celiac disease patients.  
In chapter 4 we investigate the safety of oats for consumption by celiac disease 
patients. We confirmed that commercially available oats are without exception con-
taminated with other cereals. Perhaps more importantly, we demonstrate that varia-
bility exists in the level of T cell stimulatory gluten like peptides in a panel of oats varie-
ties tested, opening the way to select and/or breed oats varieties that contain no 
harmful gluten-like proteins.  
In chapter 5 we investigate the potential of AN-PEP, a prolyl-endoprotease pro-
duced by the microorganism Aspergillus niger, to degrade gluten in an artificial gastro-
intestinal tract system. The enzyme proved very efficient in degrading all toxic epitopes 
in this system, even when a complex meal was introduced. These “in vitro” studies 
now justify a clinical trial to assess the safety and effectiveness of the enzyme for glu-
ten degradation in patients. 
In chapter 6 I discuss how the results may lead to novel treatment modalities and 





























Wat is bekend over coeliakie?  
Coeliakie is een van de meest voorkomende voedselintoleranties, ongeveer 1% van de 
bevolking is een coeliakie patiënt. Het is bekend dat coeliakie wordt veroorzaakt door 
inname van gluten, eiwitten in tarwe, en gelijkaardige eiwitten in granen zoals gerst, 
rogge en triticale (een kruising tussen tarwe en rogge). De meest voorkomende klach-
ten van patiënten zijn buikpijn, diarree en braken. Ook neurologische symptomen, 
onvruchtbaarheid en vertraging van de groei kunnen optreden. Voor een positieve 
diagnose van coeliakie is een histologisch onderzoek van een dunne darm biopsie en 
een klinische verbetering op een glutenvrij dieet nodig. Niet invasieve, serologische 
testen zijn sinds enkele jaren beschikbaar. Deze meten de aanwezigheid en titer van 
IgA en/of IgG antilichamen tegen gliadine, gedeamideerd gliadine, endomysium en tTg. 
Bijna zonder uitzondering ontwikkelt coeliakie zich bij genetisch gepredisponeerde 
individuen: meer dan 98% van de patiënten zijn HLA-DQ2 of HLA-DQ8 positief. Naast 
de genetische component beïnvloeden ook andere factoren de kans op ziekte ontwik-
keling, zoals infecties en borstvoeding. 
Coeliakie is een immuun gemedieerde ziekte waarbij gluten peptiden in contact 
komen met gluten-specifieke T-cellen in de dunne darm die een ontsteking veroorza-
ken. Deze T-cellen kunnen alleen worden geïsoleerd uit de dunne darm van patiënten 
en niet van gezonde controles. Gluten bevat veel sequenties die rijk zijn in het amino-
zuur proline en daardoor ongevoelig zijn voor degradatie in het maag-darmkanaal. 
Bovendien bevat gluten het aminozuur glutamine dat door het enzym weefsteltrans-
glutaminase gemodificeerd kan worden. Door deze modificatie ontstaan gluten pepti-
den die veel beter door T-cellen herkend worden en de ontsteking verergeren. Als 
gevolg van de ontsteking verliest het slijmvlies van de  dunne darm zijn villi waardoor 
het absorptieoppervlak van de darm sterk vermindert. Dit draagt bij aan de specifieke 
symptomen. 
De huidige behandeling van coeliakie is een strikt levenslang glutenvrij dieet. Het 
wijdverspreide gebruik van gluten en gluten-afgeleid zetmeel in de voedingsindustrie 
maakt het glutenvrije dieet uitdagend. Het is niet verwonderlijk dat een aanzienlijk 
deel van de patiënten, vooral jongeren, geïnteresseerd is  in alternatieve behandeling-
en die gluten consumptie mogelijk zou maken. 
  
 
De inhoud van het proefschrift 
Mijn project, beschreven in dit proefschrift, was gericht op de ontwikkeling van alter-
natieven voor het glutenvrije dieet. Twee verschillende benaderingen werden onder-
zocht: het gebruik van enzymatische suppletie en de identificatie en/of ontwikkeling 
van een minder/niet-toxisch graan.  
Hoofdstuk 1 is een algemene inleiding op coeliakie. 
In hoofdstuk 2 wordt de karakterisering van monoklonale antilichamen tegen T-
cel stimulerende gluten peptiden beschreven. Hun reactiviteit tegen gluten en gluten-
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achtige eiwitten in tarwe, gerst, rogge en haver werd bepaald en vergeleken met die 
van gluten reactieve T-cellen. De resultaten tonen aan dat de antilichaam en T-cel 
reactiviteit patronen aanzienlijk overlappen, wat aangeeft dat deze antilichamen ge-
bruikt kunnen worden om toxische sequenties in gluten te detecteren. Vervolgens 
werden deze antilichamen gebruikt in de studies die gericht waren op de ontwikkeling 
van alternativen voor het glutenvrije dieet. 
In hoofdstuk 3 stellen we een nieuwe strategie voor om niet-toxische gluten te 
genereren. Onze experimenten toonden aan dat in bepaalde diploïde tarwe rassen een 
niet-immunogene gluten variant aanwezig is die één aminozuur verschilt met de im-
munogenische variant. Bovendien vonden we dat door de invoering van deze natuur-
lijk voorkomende aminozuur substitutie in andere gluten epitopen hun T-cel stimule-
rende activiteit eveneens werd geëlimineerd. Deze benadering kan dus worden ge-
bruikt om gluten eiwitten te genereren die geen T-cel stimulerende activiteit meer 
bevatten en dus vermoedelijk veilig zijn voor consumptie door coeliakie patiënten. 
In hoofdstuk 4 onderzoeken we de veiligheid van haver voor consumptie door co-
eliakie patiënten. We hebben bevestigd dat zonder uitzondering alle commercieel 
verkrijgbare haver verontreinigd is met andere granen en dus onveilig voor consumptie 
door coeliakiepatiënten. Bovendien vonden we dat er variabiliteit bestaat in het niveau 
van de T-cel stimulerende peptiden tussen havervariëteiten. Dit biedt de mogelijkheid 
om havervariëteiten te selecteren en/of te ontwikkelen die geen schadelijke gluten-
achtige eiwitten bevatten. 
In hoofdstuk 5 bepaalden we het potentieel van AN-PEP, een prolyl-endoprotease 
geproduceerd door het micro-organisme Aspergillus niger, om gluten af te breken in 
een kunstmatig maagdarmkanaal systeem. Het enzym bleek zeer efficiënt te zijn in het 
afbreken van alle toxische gluten epitopen, zelfs als een complexe maaltijd was inge-
voerd. Deze "in vitro" onderzoeken rechtvaardigen nu een klinische studie om de vei-
ligheid en effectiviteit van het enzym te bepalen. Dit kan mogelijk leiden tot een en-
zympil die patiënten kunnen gebruiken om gluten consumptie mogelijk te maken. 
In hoofdstuk 6 bediscussieer ik hoe deze resultaten kunnen leiden tot nieuwe be-









Publ   
 
 
List of publications 
 












LIST OF PUBLICATIONS 
 
 
• Stepniak D., Spaenij-Dekking L., Mitea C., Moester M., de Ru A., Baak-Pablo R., van 
Veelen P. Edens L., Koning F. – Highly efficient gluten degradation with a newly 
identified prolyl endoprotease: implications for celiac disease. Am J Physiol Gastro-
intest Liver Physiol 2006 Oct;291(4):G621-9 
 
• Mitea C., Havenaar R., Drijfhout J. W., Edens L., Dekking L., Koning F. – Efficient 
degradation of gluten by a prolyl endoprotease in a gastrointestinal model: impli-
cations for coeliac disease. Gut. 2008 Jan;57(1):25-32 
 
• Mitea C., Kooy-Winkelaar Y., van Veelen P., de Ru A., Drijfhout J. W., Koning F., 
Dekking L. – Fine specificity of monoclonal antibodies against disease inducing 
peptides present in the gluteome. Am J Clin Nutr. 2008 Oct;88(4):1057-66 
 
• Mitea C, Salentijn EM, van Veelen P, Goryunova SV, van der Meer IM, van den 
Broeck HC, Mujico JR, Monserrat V, Gilissen LJ, Drijfhout JW, Dekking L, Koning F, 
Smulders MJ. – A universal approach to eliminate antigenic properties of alpha-
gliadin peptides in celiac disease. PLoS ONE 2010 Dec 16;5(12):e15637 
 
• Mitea C, Mujico JR, Gilissen LJ, de Ru A, van Veelen P,  Smulders MJ, Koning F. -
Natural variation in avenin epitopes among oat varieties: implications for Celiac 
Disease, Journal of Cereal Science, in press 
 
• Dekking L., Mitea C., Stepniak D., Baak-Pablo R., Kooy-Winkelaar Y., Edens L.,  
Koning F. – Detection and detoxification of gluten. Proceedings of the 21
st
 Meeting 


































The author of this thesis, Doina Cristina Mitea was born in Cluj-Napoca, Romania on 
the 28
th
 of March 1978. She attended secondary school at the “Tiberiu Popoviciu” 
Computer Science High School in Cluj-Napoca, where she got her Romanian Baccalau-
reate diploma in June 1997. From 1998 she studied Medicine at the “Iuliu Hatieganu” 
University of Medicine and Pharmacy, Cluj-Napoca. During her medical study she per-
formed a 3-months research project at the department of Immunohematology and 
Blood Transfusion of the Leiden University Medical Center, under the supervision of 
Prof. dr. Frits Koning and dr. Liesbeth Dekking, investigating the molecular basis of 
celiac disease. After receiving her MD diploma in September 2004, she returned in the 
group of Prof. dr. Frits Koning to carry out the present PhD research project that she 
completed in April 2009. The results of her research led to scientific publications, post-
er and oral presentations during more international congresses and symposia. In May 
2009 she started a 4-year training program in the Leiden University Medical Center to 































Aa    amino acid;   
ACN    acetonitrile 
AN-PEP  Aspergillus niger prolyl endoprotease 
BSA  bovine serum albumin 
CD  celiac disease 
cpm   counts per minute 
ELISA  enzyme-linked immunosorbent assay 
GI  gastrointestinal 
Glt  glutenin 
Glia  gliadin  
HMW   high molecular weight 
HLA   Human leukocyte antigen 
IMDM  Iscove's modified Dulbecco's media  
LMW  low molecular weight 
mAb   monoclonal antibody 
NMP  N-methyl-2-pyrrolidone 
PEP  prolyl endopeptidase 
PVDF  Polyvinylidene fluoride  
PBMC   peripheral blood mononuclear cell 
RT  room temperature 
Rp HPLC  reversed phase high performance liquid chromatography 
SDS-PAGE sodiumdodecyl sulphate poly-acrylamide gel electrophoresis  
TIM  TNO gastrointestinal model 
tTG;  tissue transglutaminase 
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